CN105431172A - 炎症性病症的治疗 - Google Patents
炎症性病症的治疗 Download PDFInfo
- Publication number
- CN105431172A CN105431172A CN201480030407.7A CN201480030407A CN105431172A CN 105431172 A CN105431172 A CN 105431172A CN 201480030407 A CN201480030407 A CN 201480030407A CN 105431172 A CN105431172 A CN 105431172A
- Authority
- CN
- China
- Prior art keywords
- compound
- hydrocarbyl
- disease
- use according
- nalidixic acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000011282 treatment Methods 0.000 title claims abstract description 24
- 208000027866 inflammatory disease Diseases 0.000 title claims abstract description 15
- MHWLWQUZZRMNGJ-UHFFFAOYSA-N nalidixic acid Chemical compound C1=C(C)N=C2N(CC)C=C(C(O)=O)C(=O)C2=C1 MHWLWQUZZRMNGJ-UHFFFAOYSA-N 0.000 claims abstract description 61
- 229960000210 nalidixic acid Drugs 0.000 claims abstract description 51
- 150000001875 compounds Chemical class 0.000 claims description 68
- 150000003839 salts Chemical class 0.000 claims description 25
- 208000006673 asthma Diseases 0.000 claims description 15
- 239000000203 mixture Substances 0.000 claims description 15
- 125000001183 hydrocarbyl group Chemical group 0.000 claims description 13
- 229910052736 halogen Inorganic materials 0.000 claims description 12
- 150000002367 halogens Chemical class 0.000 claims description 12
- JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 claims description 12
- 206010012438 Dermatitis atopic Diseases 0.000 claims description 11
- 201000008937 atopic dermatitis Diseases 0.000 claims description 11
- 201000010099 disease Diseases 0.000 claims description 11
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 11
- 210000004072 lung Anatomy 0.000 claims description 11
- 150000003431 steroids Chemical class 0.000 claims description 11
- 201000004681 Psoriasis Diseases 0.000 claims description 10
- 239000003814 drug Substances 0.000 claims description 10
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims description 9
- 206010039710 Scleroderma Diseases 0.000 claims description 9
- 230000000844 anti-bacterial effect Effects 0.000 claims description 9
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 9
- 206010009900 Colitis ulcerative Diseases 0.000 claims description 8
- 208000011231 Crohn disease Diseases 0.000 claims description 8
- 201000006704 Ulcerative Colitis Diseases 0.000 claims description 8
- 238000012384 transportation and delivery Methods 0.000 claims description 8
- 210000001035 gastrointestinal tract Anatomy 0.000 claims description 7
- 239000003862 glucocorticoid Substances 0.000 claims description 7
- 239000008194 pharmaceutical composition Substances 0.000 claims description 7
- 229940037128 systemic glucocorticoids Drugs 0.000 claims description 7
- 230000001684 chronic effect Effects 0.000 claims description 6
- 229960000890 hydrocortisone Drugs 0.000 claims description 6
- 229910052739 hydrogen Inorganic materials 0.000 claims description 6
- 230000004968 inflammatory condition Effects 0.000 claims description 6
- 238000000034 method Methods 0.000 claims description 6
- 208000028169 periodontal disease Diseases 0.000 claims description 6
- 238000006467 substitution reaction Methods 0.000 claims description 6
- 201000000596 systemic lupus erythematosus Diseases 0.000 claims description 6
- 230000000699 topical effect Effects 0.000 claims description 6
- 239000002253 acid Substances 0.000 claims description 5
- 239000013543 active substance Substances 0.000 claims description 5
- 125000000592 heterocycloalkyl group Chemical group 0.000 claims description 5
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 5
- 230000002265 prevention Effects 0.000 claims description 5
- 210000003491 skin Anatomy 0.000 claims description 5
- 229940124597 therapeutic agent Drugs 0.000 claims description 5
- FUFLCEKSBBHCMO-UHFFFAOYSA-N 11-dehydrocorticosterone Natural products O=C1CCC2(C)C3C(=O)CC(C)(C(CC4)C(=O)CO)C4C3CCC2=C1 FUFLCEKSBBHCMO-UHFFFAOYSA-N 0.000 claims description 4
- MFYSYFVPBJMHGN-ZPOLXVRWSA-N Cortisone Chemical compound O=C1CC[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 MFYSYFVPBJMHGN-ZPOLXVRWSA-N 0.000 claims description 4
- MFYSYFVPBJMHGN-UHFFFAOYSA-N Cortisone Natural products O=C1CCC2(C)C3C(=O)CC(C)(C(CC4)(O)C(=O)CO)C4C3CCC2=C1 MFYSYFVPBJMHGN-UHFFFAOYSA-N 0.000 claims description 4
- 208000007342 Diabetic Nephropathies Diseases 0.000 claims description 4
- 208000009329 Graft vs Host Disease Diseases 0.000 claims description 4
- 208000010159 IgA glomerulonephritis Diseases 0.000 claims description 4
- 206010021263 IgA nephropathy Diseases 0.000 claims description 4
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims description 4
- FQISKWAFAHGMGT-SGJOWKDISA-M Methylprednisolone sodium succinate Chemical compound [Na+].C([C@@]12C)=CC(=O)C=C1[C@@H](C)C[C@@H]1[C@@H]2[C@@H](O)C[C@]2(C)[C@@](O)(C(=O)COC(=O)CCC([O-])=O)CC[C@H]21 FQISKWAFAHGMGT-SGJOWKDISA-M 0.000 claims description 4
- 208000014151 Stomatognathic disease Diseases 0.000 claims description 4
- 229960004544 cortisone Drugs 0.000 claims description 4
- 229960003957 dexamethasone Drugs 0.000 claims description 4
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 claims description 4
- 208000033679 diabetic kidney disease Diseases 0.000 claims description 4
- 208000007565 gingivitis Diseases 0.000 claims description 4
- 208000024908 graft versus host disease Diseases 0.000 claims description 4
- 229960004584 methylprednisolone Drugs 0.000 claims description 4
- 201000006417 multiple sclerosis Diseases 0.000 claims description 4
- 201000008482 osteoarthritis Diseases 0.000 claims description 4
- 229960005205 prednisolone Drugs 0.000 claims description 4
- OIGNJSKKLXVSLS-VWUMJDOOSA-N prednisolone Chemical compound O=C1C=C[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 OIGNJSKKLXVSLS-VWUMJDOOSA-N 0.000 claims description 4
- 208000023504 respiratory system disease Diseases 0.000 claims description 4
- 206010039073 rheumatoid arthritis Diseases 0.000 claims description 4
- 208000017520 skin disease Diseases 0.000 claims description 4
- 229960002537 betamethasone Drugs 0.000 claims description 3
- UREBDLICKHMUKA-DVTGEIKXSA-N betamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-DVTGEIKXSA-N 0.000 claims description 3
- 239000003795 chemical substances by application Substances 0.000 claims description 3
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 claims description 3
- 125000004076 pyridyl group Chemical group 0.000 claims description 3
- VOVIALXJUBGFJZ-KWVAZRHASA-N Budesonide Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@@H]2[C@@H]1[C@@H]1C[C@H]3OC(CCC)O[C@@]3(C(=O)CO)[C@@]1(C)C[C@@H]2O VOVIALXJUBGFJZ-KWVAZRHASA-N 0.000 claims description 2
- PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 claims description 2
- 108010036949 Cyclosporine Proteins 0.000 claims description 2
- 208000016192 Demyelinating disease Diseases 0.000 claims description 2
- 206010018364 Glomerulonephritis Diseases 0.000 claims description 2
- 208000005777 Lupus Nephritis Diseases 0.000 claims description 2
- 208000001132 Osteoporosis Diseases 0.000 claims description 2
- MKPDWECBUAZOHP-AFYJWTTESA-N Paramethasone Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@@H]1[C@@H]2[C@@H]2C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]2(C)C[C@@H]1O MKPDWECBUAZOHP-AFYJWTTESA-N 0.000 claims description 2
- 229940125715 antihistaminic agent Drugs 0.000 claims description 2
- 239000000739 antihistaminic agent Substances 0.000 claims description 2
- 229940092705 beclomethasone Drugs 0.000 claims description 2
- NBMKJKDGKREAPL-DVTGEIKXSA-N beclomethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(Cl)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O NBMKJKDGKREAPL-DVTGEIKXSA-N 0.000 claims description 2
- 229960004436 budesonide Drugs 0.000 claims description 2
- 229960001265 ciclosporin Drugs 0.000 claims description 2
- 229960001259 diclofenac Drugs 0.000 claims description 2
- DCOPUUMXTXDBNB-UHFFFAOYSA-N diclofenac Chemical compound OC(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl DCOPUUMXTXDBNB-UHFFFAOYSA-N 0.000 claims description 2
- 229960002390 flurbiprofen Drugs 0.000 claims description 2
- SYTBZMRGLBWNTM-UHFFFAOYSA-N flurbiprofen Chemical compound FC1=CC(C(C(O)=O)C)=CC=C1C1=CC=CC=C1 SYTBZMRGLBWNTM-UHFFFAOYSA-N 0.000 claims description 2
- 229960002714 fluticasone Drugs 0.000 claims description 2
- MGNNYOODZCAHBA-GQKYHHCASA-N fluticasone Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2C[C@@H](C)[C@@](C(=O)SCF)(O)[C@@]2(C)C[C@@H]1O MGNNYOODZCAHBA-GQKYHHCASA-N 0.000 claims description 2
- OZWKMVRBQXNZKK-UHFFFAOYSA-N ketorolac Chemical compound OC(=O)C1CCN2C1=CC=C2C(=O)C1=CC=CC=C1 OZWKMVRBQXNZKK-UHFFFAOYSA-N 0.000 claims description 2
- 229960004752 ketorolac Drugs 0.000 claims description 2
- 229960001664 mometasone Drugs 0.000 claims description 2
- QLIIKPVHVRXHRI-CXSFZGCWSA-N mometasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(Cl)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CCl)(O)[C@@]1(C)C[C@@H]2O QLIIKPVHVRXHRI-CXSFZGCWSA-N 0.000 claims description 2
- 208000015122 neurodegenerative disease Diseases 0.000 claims description 2
- 229960002858 paramethasone Drugs 0.000 claims description 2
- YUWPMEXLKGOSBF-GACAOOTBSA-N Anecortave acetate Chemical compound O=C1CC[C@]2(C)C3=CC[C@]4(C)[C@](C(=O)COC(=O)C)(O)CC[C@H]4[C@@H]3CCC2=C1 YUWPMEXLKGOSBF-GACAOOTBSA-N 0.000 claims 1
- 102400000068 Angiostatin Human genes 0.000 claims 1
- 108010079709 Angiostatins Proteins 0.000 claims 1
- ZKLPARSLTMPFCP-UHFFFAOYSA-N Cetirizine Chemical compound C1CN(CCOCC(=O)O)CCN1C(C=1C=CC(Cl)=CC=1)C1=CC=CC=C1 ZKLPARSLTMPFCP-UHFFFAOYSA-N 0.000 claims 1
- 229930105110 Cyclosporin A Natural products 0.000 claims 1
- 102000004127 Cytokines Human genes 0.000 claims 1
- 108090000695 Cytokines Proteins 0.000 claims 1
- 208000018035 Dental disease Diseases 0.000 claims 1
- ZCVMWBYGMWKGHF-UHFFFAOYSA-N Ketotifene Chemical compound C1CN(C)CCC1=C1C2=CC=CC=C2CC(=O)C2=C1C=CS2 ZCVMWBYGMWKGHF-UHFFFAOYSA-N 0.000 claims 1
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 claims 1
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 claims 1
- 229960001232 anecortave Drugs 0.000 claims 1
- 230000033115 angiogenesis Effects 0.000 claims 1
- 230000000964 angiostatic effect Effects 0.000 claims 1
- FZCSTZYAHCUGEM-UHFFFAOYSA-N aspergillomarasmine B Natural products OC(=O)CNC(C(O)=O)CNC(C(O)=O)CC(O)=O FZCSTZYAHCUGEM-UHFFFAOYSA-N 0.000 claims 1
- 229940082638 cardiac stimulant phosphodiesterase inhibitors Drugs 0.000 claims 1
- 229960001803 cetirizine Drugs 0.000 claims 1
- 239000003102 growth factor Substances 0.000 claims 1
- 229960004958 ketotifen Drugs 0.000 claims 1
- 150000002617 leukotrienes Chemical class 0.000 claims 1
- 229960003088 loratadine Drugs 0.000 claims 1
- JCCNYMKQOSZNPW-UHFFFAOYSA-N loratadine Chemical compound C1CN(C(=O)OCC)CCC1=C1C2=NC=CC=C2CCC2=CC(Cl)=CC=C21 JCCNYMKQOSZNPW-UHFFFAOYSA-N 0.000 claims 1
- 239000002571 phosphodiesterase inhibitor Substances 0.000 claims 1
- 102000004196 processed proteins & peptides Human genes 0.000 claims 1
- 108090000765 processed proteins & peptides Proteins 0.000 claims 1
- 230000002685 pulmonary effect Effects 0.000 claims 1
- 238000012385 systemic delivery Methods 0.000 claims 1
- UHTHHESEBZOYNR-UHFFFAOYSA-N vandetanib Chemical compound COC1=CC(C(/N=CN2)=N/C=3C(=CC(Br)=CC=3)F)=C2C=C1OCC1CCN(C)CC1 UHTHHESEBZOYNR-UHFFFAOYSA-N 0.000 claims 1
- 229960000241 vandetanib Drugs 0.000 claims 1
- MWLSOWXNZPKENC-SSDOTTSWSA-N zileuton Chemical compound C1=CC=C2SC([C@H](N(O)C(N)=O)C)=CC2=C1 MWLSOWXNZPKENC-SSDOTTSWSA-N 0.000 claims 1
- 229960005332 zileuton Drugs 0.000 claims 1
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 18
- 210000003630 histaminocyte Anatomy 0.000 description 14
- 230000003110 anti-inflammatory effect Effects 0.000 description 12
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 12
- -1 ebafloxacin Chemical compound 0.000 description 12
- 239000002953 phosphate buffered saline Substances 0.000 description 12
- 210000004027 cell Anatomy 0.000 description 10
- 229960001340 histamine Drugs 0.000 description 9
- 210000001519 tissue Anatomy 0.000 description 9
- 239000003242 anti bacterial agent Substances 0.000 description 8
- 230000005764 inhibitory process Effects 0.000 description 8
- 125000004429 atom Chemical group 0.000 description 7
- 238000009472 formulation Methods 0.000 description 7
- 208000015181 infectious disease Diseases 0.000 description 7
- 210000000056 organ Anatomy 0.000 description 7
- 238000012360 testing method Methods 0.000 description 7
- 201000004624 Dermatitis Diseases 0.000 description 6
- 241001465754 Metazoa Species 0.000 description 6
- 108010058846 Ovalbumin Proteins 0.000 description 6
- 229940088710 antibiotic agent Drugs 0.000 description 6
- 210000003979 eosinophil Anatomy 0.000 description 6
- 229940092253 ovalbumin Drugs 0.000 description 6
- 208000023275 Autoimmune disease Diseases 0.000 description 5
- 125000004432 carbon atom Chemical group C* 0.000 description 5
- 238000006243 chemical reaction Methods 0.000 description 5
- 229940079593 drug Drugs 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 230000002757 inflammatory effect Effects 0.000 description 5
- 238000011200 topical administration Methods 0.000 description 5
- 102000004145 Annexin A1 Human genes 0.000 description 4
- 108090000663 Annexin A1 Proteins 0.000 description 4
- 206010061218 Inflammation Diseases 0.000 description 4
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 description 4
- 208000037976 chronic inflammation Diseases 0.000 description 4
- 208000037893 chronic inflammatory disorder Diseases 0.000 description 4
- 230000004054 inflammatory process Effects 0.000 description 4
- 230000000155 isotopic effect Effects 0.000 description 4
- BHMBVRSPMRCCGG-OUTUXVNYSA-N prostaglandin D2 Chemical compound CCCCC[C@H](O)\C=C\[C@@H]1[C@@H](C\C=C/CCCC(O)=O)[C@@H](O)CC1=O BHMBVRSPMRCCGG-OUTUXVNYSA-N 0.000 description 4
- LISFMEBWQUVKPJ-UHFFFAOYSA-N quinolin-2-ol Chemical compound C1=CC=C2NC(=O)C=CC2=C1 LISFMEBWQUVKPJ-UHFFFAOYSA-N 0.000 description 4
- 229920006395 saturated elastomer Polymers 0.000 description 4
- 210000003954 umbilical cord Anatomy 0.000 description 4
- OQANPHBRHBJGNZ-FYJGNVAPSA-N (3e)-6-oxo-3-[[4-(pyridin-2-ylsulfamoyl)phenyl]hydrazinylidene]cyclohexa-1,4-diene-1-carboxylic acid Chemical compound C1=CC(=O)C(C(=O)O)=C\C1=N\NC1=CC=C(S(=O)(=O)NC=2N=CC=CC=2)C=C1 OQANPHBRHBJGNZ-FYJGNVAPSA-N 0.000 description 3
- 208000002874 Acne Vulgaris Diseases 0.000 description 3
- 208000028185 Angioedema Diseases 0.000 description 3
- 101000741929 Caenorhabditis elegans Serine/threonine-protein phosphatase 2A catalytic subunit Proteins 0.000 description 3
- 206010012442 Dermatitis contact Diseases 0.000 description 3
- 206010015218 Erythema multiforme Diseases 0.000 description 3
- 241000699666 Mus <mouse, genus> Species 0.000 description 3
- 206010034277 Pemphigoid Diseases 0.000 description 3
- 229920001213 Polysorbate 20 Polymers 0.000 description 3
- 201000001263 Psoriatic Arthritis Diseases 0.000 description 3
- 208000036824 Psoriatic arthropathy Diseases 0.000 description 3
- RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical compound C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 description 3
- 241001303601 Rosacea Species 0.000 description 3
- 208000024780 Urticaria Diseases 0.000 description 3
- 206010000496 acne Diseases 0.000 description 3
- 208000002029 allergic contact dermatitis Diseases 0.000 description 3
- 230000003115 biocidal effect Effects 0.000 description 3
- 239000007853 buffer solution Substances 0.000 description 3
- 208000000594 bullous pemphigoid Diseases 0.000 description 3
- NCEXYHBECQHGNR-UHFFFAOYSA-N chembl421 Chemical compound C1=C(O)C(C(=O)O)=CC(N=NC=2C=CC(=CC=2)S(=O)(=O)NC=2N=CC=CC=2)=C1 NCEXYHBECQHGNR-UHFFFAOYSA-N 0.000 description 3
- 230000006378 damage Effects 0.000 description 3
- 206010025135 lupus erythematosus Diseases 0.000 description 3
- 230000000813 microbial effect Effects 0.000 description 3
- 229910052757 nitrogen Inorganic materials 0.000 description 3
- 229910052760 oxygen Inorganic materials 0.000 description 3
- 208000017983 photosensitivity disease Diseases 0.000 description 3
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 3
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 3
- 230000003389 potentiating effect Effects 0.000 description 3
- 201000004700 rosacea Diseases 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 229960001940 sulfasalazine Drugs 0.000 description 3
- 229910052717 sulfur Inorganic materials 0.000 description 3
- 239000006228 supernatant Substances 0.000 description 3
- 238000002560 therapeutic procedure Methods 0.000 description 3
- XUBOMFCQGDBHNK-JTQLQIEISA-N (S)-gatifloxacin Chemical compound FC1=CC(C(C(C(O)=O)=CN2C3CC3)=O)=C2C(OC)=C1N1CCN[C@@H](C)C1 XUBOMFCQGDBHNK-JTQLQIEISA-N 0.000 description 2
- HETSDWRDICBRSQ-UHFFFAOYSA-N 3h-quinolin-4-one Chemical class C1=CC=C2C(=O)CC=NC2=C1 HETSDWRDICBRSQ-UHFFFAOYSA-N 0.000 description 2
- DPSPPJIUMHPXMA-UHFFFAOYSA-N 9-fluoro-5-methyl-1-oxo-6,7-dihydro-1H,5H-pyrido[3,2,1-ij]quinoline-2-carboxylic acid Chemical compound C1CC(C)N2C=C(C(O)=O)C(=O)C3=C2C1=CC(F)=C3 DPSPPJIUMHPXMA-UHFFFAOYSA-N 0.000 description 2
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 2
- 208000026872 Addison Disease Diseases 0.000 description 2
- 208000024827 Alzheimer disease Diseases 0.000 description 2
- 206010002198 Anaphylactic reaction Diseases 0.000 description 2
- 206010002556 Ankylosing Spondylitis Diseases 0.000 description 2
- 201000001320 Atherosclerosis Diseases 0.000 description 2
- 206010069002 Autoimmune pancreatitis Diseases 0.000 description 2
- 210000002237 B-cell of pancreatic islet Anatomy 0.000 description 2
- 206010008874 Chronic Fatigue Syndrome Diseases 0.000 description 2
- 206010008909 Chronic Hepatitis Diseases 0.000 description 2
- 206010010741 Conjunctivitis Diseases 0.000 description 2
- 206010012689 Diabetic retinopathy Diseases 0.000 description 2
- 208000003556 Dry Eye Syndromes Diseases 0.000 description 2
- 206010013774 Dry eye Diseases 0.000 description 2
- 238000002965 ELISA Methods 0.000 description 2
- 201000009273 Endometriosis Diseases 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 208000001351 Epiretinal Membrane Diseases 0.000 description 2
- UGJMXCAKCUNAIE-UHFFFAOYSA-N Gabapentin Chemical compound OC(=O)CC1(CN)CCCCC1 UGJMXCAKCUNAIE-UHFFFAOYSA-N 0.000 description 2
- 208000024869 Goodpasture syndrome Diseases 0.000 description 2
- 206010020751 Hypersensitivity Diseases 0.000 description 2
- 201000009794 Idiopathic Pulmonary Fibrosis Diseases 0.000 description 2
- UETNIIAIRMUTSM-UHFFFAOYSA-N Jacareubin Natural products CC1(C)OC2=CC3Oc4c(O)c(O)ccc4C(=O)C3C(=C2C=C1)O UETNIIAIRMUTSM-UHFFFAOYSA-N 0.000 description 2
- 208000001344 Macular Edema Diseases 0.000 description 2
- 206010025415 Macular oedema Diseases 0.000 description 2
- 208000026072 Motor neurone disease Diseases 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- CMWTZPSULFXXJA-UHFFFAOYSA-N Naproxen Natural products C1=C(C(C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-UHFFFAOYSA-N 0.000 description 2
- MITFXPHMIHQXPI-UHFFFAOYSA-N Oraflex Chemical compound N=1C2=CC(C(C(O)=O)C)=CC=C2OC=1C1=CC=C(Cl)C=C1 MITFXPHMIHQXPI-UHFFFAOYSA-N 0.000 description 2
- KYGZCKSPAKDVKC-UHFFFAOYSA-N Oxolinic acid Chemical compound C1=C2N(CC)C=C(C(O)=O)C(=O)C2=CC2=C1OCO2 KYGZCKSPAKDVKC-UHFFFAOYSA-N 0.000 description 2
- 208000018737 Parkinson disease Diseases 0.000 description 2
- 208000029082 Pelvic Inflammatory Disease Diseases 0.000 description 2
- 102000004160 Phosphoric Monoester Hydrolases Human genes 0.000 description 2
- 108090000608 Phosphoric Monoester Hydrolases Proteins 0.000 description 2
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 2
- 102000003923 Protein Kinase C Human genes 0.000 description 2
- 108090000315 Protein Kinase C Proteins 0.000 description 2
- 208000002367 Retinal Perforations Diseases 0.000 description 2
- 208000021386 Sjogren Syndrome Diseases 0.000 description 2
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 description 2
- 206010046851 Uveitis Diseases 0.000 description 2
- 238000010306 acid treatment Methods 0.000 description 2
- 208000009621 actinic keratosis Diseases 0.000 description 2
- 210000004100 adrenal gland Anatomy 0.000 description 2
- 230000036783 anaphylactic response Effects 0.000 description 2
- 208000003455 anaphylaxis Diseases 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 239000003435 antirheumatic agent Substances 0.000 description 2
- NWGGKKGAFZIVBJ-UHFFFAOYSA-N antrafenine Chemical compound FC(F)(F)C1=CC=CC(N2CCN(CCOC(=O)C=3C(=CC=CC=3)NC=3C4=CC=C(C=C4N=CC=3)C(F)(F)F)CC2)=C1 NWGGKKGAFZIVBJ-UHFFFAOYSA-N 0.000 description 2
- CNBGNNVCVSKAQZ-UHFFFAOYSA-N benzydamine Chemical compound C12=CC=CC=C2C(OCCCN(C)C)=NN1CC1=CC=CC=C1 CNBGNNVCVSKAQZ-UHFFFAOYSA-N 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 229910052799 carbon Inorganic materials 0.000 description 2
- 210000003169 central nervous system Anatomy 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- JCKYGMPEJWAADB-UHFFFAOYSA-N chlorambucil Chemical compound OC(=O)CCCC1=CC=C(N(CCCl)CCCl)C=C1 JCKYGMPEJWAADB-UHFFFAOYSA-N 0.000 description 2
- 229960004630 chlorambucil Drugs 0.000 description 2
- 208000025302 chronic primary adrenal insufficiency Diseases 0.000 description 2
- 229960004621 cinoxacin Drugs 0.000 description 2
- VDUWPHTZYNWKRN-UHFFFAOYSA-N cinoxacin Chemical compound C1=C2N(CC)N=C(C(O)=O)C(=O)C2=CC2=C1OCO2 VDUWPHTZYNWKRN-UHFFFAOYSA-N 0.000 description 2
- MYSWGUAQZAJSOK-UHFFFAOYSA-N ciprofloxacin Chemical compound C12=CC(N3CCNCC3)=C(F)C=C2C(=O)C(C(=O)O)=CN1C1CC1 MYSWGUAQZAJSOK-UHFFFAOYSA-N 0.000 description 2
- 239000003246 corticosteroid Substances 0.000 description 2
- 229960001334 corticosteroids Drugs 0.000 description 2
- 125000004122 cyclic group Chemical group 0.000 description 2
- 230000003013 cytotoxicity Effects 0.000 description 2
- 231100000135 cytotoxicity Toxicity 0.000 description 2
- 239000002988 disease modifying antirheumatic drug Substances 0.000 description 2
- 231100000673 dose–response relationship Toxicity 0.000 description 2
- 210000003499 exocrine gland Anatomy 0.000 description 2
- 229960000702 flumequine Drugs 0.000 description 2
- 229960003923 gatifloxacin Drugs 0.000 description 2
- 208000006454 hepatitis Diseases 0.000 description 2
- 125000005842 heteroatom Chemical group 0.000 description 2
- 230000028993 immune response Effects 0.000 description 2
- 238000003018 immunoassay Methods 0.000 description 2
- 239000003018 immunosuppressive agent Substances 0.000 description 2
- 238000000099 in vitro assay Methods 0.000 description 2
- 238000005462 in vivo assay Methods 0.000 description 2
- 230000002779 inactivation Effects 0.000 description 2
- CGIGDMFJXJATDK-UHFFFAOYSA-N indomethacin Chemical compound CC1=C(CC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 CGIGDMFJXJATDK-UHFFFAOYSA-N 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- 208000036971 interstitial lung disease 2 Diseases 0.000 description 2
- 201000006334 interstitial nephritis Diseases 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- 208000002780 macular degeneration Diseases 0.000 description 2
- 208000029233 macular holes Diseases 0.000 description 2
- 201000010230 macular retinal edema Diseases 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 208000005264 motor neuron disease Diseases 0.000 description 2
- 238000010172 mouse model Methods 0.000 description 2
- 208000029766 myalgic encephalomeyelitis/chronic fatigue syndrome Diseases 0.000 description 2
- 229960002009 naproxen Drugs 0.000 description 2
- CMWTZPSULFXXJA-VIFPVBQESA-N naproxen Chemical compound C1=C([C@H](C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-VIFPVBQESA-N 0.000 description 2
- 230000003472 neutralizing effect Effects 0.000 description 2
- 230000003287 optical effect Effects 0.000 description 2
- 229960000321 oxolinic acid Drugs 0.000 description 2
- 239000008188 pellet Substances 0.000 description 2
- CPJSUEIXXCENMM-UHFFFAOYSA-N phenacetin Chemical compound CCOC1=CC=C(NC(C)=O)C=C1 CPJSUEIXXCENMM-UHFFFAOYSA-N 0.000 description 2
- BHMBVRSPMRCCGG-UHFFFAOYSA-N prostaglandine D2 Natural products CCCCCC(O)C=CC1C(CC=CCCCC(O)=O)C(O)CC1=O BHMBVRSPMRCCGG-UHFFFAOYSA-N 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 206010039083 rhinitis Diseases 0.000 description 2
- WVYADZUPLLSGPU-UHFFFAOYSA-N salsalate Chemical compound OC(=O)C1=CC=CC=C1OC(=O)C1=CC=CC=C1O WVYADZUPLLSGPU-UHFFFAOYSA-N 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 125000001424 substituent group Chemical group 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 238000011287 therapeutic dose Methods 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 201000008827 tuberculosis Diseases 0.000 description 2
- 208000035408 type 1 diabetes mellitus 1 Diseases 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- RJMIEHBSYVWVIN-LLVKDONJSA-N (2r)-2-[4-(3-oxo-1h-isoindol-2-yl)phenyl]propanoic acid Chemical compound C1=CC([C@H](C(O)=O)C)=CC=C1N1C(=O)C2=CC=CC=C2C1 RJMIEHBSYVWVIN-LLVKDONJSA-N 0.000 description 1
- MDKGKXOCJGEUJW-VIFPVBQESA-N (2s)-2-[4-(thiophene-2-carbonyl)phenyl]propanoic acid Chemical compound C1=CC([C@@H](C(O)=O)C)=CC=C1C(=O)C1=CC=CS1 MDKGKXOCJGEUJW-VIFPVBQESA-N 0.000 description 1
- LJRDOKAZOAKLDU-UDXJMMFXSA-N (2s,3s,4r,5r,6r)-5-amino-2-(aminomethyl)-6-[(2r,3s,4r,5s)-5-[(1r,2r,3s,5r,6s)-3,5-diamino-2-[(2s,3r,4r,5s,6r)-3-amino-4,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-6-hydroxycyclohexyl]oxy-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl]oxyoxane-3,4-diol;sulfuric ac Chemical compound OS(O)(=O)=O.N[C@@H]1[C@@H](O)[C@H](O)[C@H](CN)O[C@@H]1O[C@H]1[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](N)C[C@@H](N)[C@@H]2O)O[C@@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)N)O[C@@H]1CO LJRDOKAZOAKLDU-UDXJMMFXSA-N 0.000 description 1
- RXZBMPWDPOLZGW-XMRMVWPWSA-N (E)-roxithromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=N/OCOCCOC)/[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 RXZBMPWDPOLZGW-XMRMVWPWSA-N 0.000 description 1
- QKDHBVNJCZBTMR-LLVKDONJSA-N (R)-temafloxacin Chemical compound C1CN[C@H](C)CN1C(C(=C1)F)=CC2=C1C(=O)C(C(O)=O)=CN2C1=CC=C(F)C=C1F QKDHBVNJCZBTMR-LLVKDONJSA-N 0.000 description 1
- JMRRMEWKBNINNT-UHFFFAOYSA-N 1,5,7-trimethyl-4-oxo-1,8-naphthyridine-3-carboxylic acid Chemical compound CN1C=C(C(C2=C(C=C(N=C12)C)C)=O)C(=O)O JMRRMEWKBNINNT-UHFFFAOYSA-N 0.000 description 1
- GHPCICSQWQDZLM-UHFFFAOYSA-N 1-(4-chlorophenyl)sulfonyl-1-methyl-3-propylurea Chemical compound CCCNC(=O)N(C)S(=O)(=O)C1=CC=C(Cl)C=C1 GHPCICSQWQDZLM-UHFFFAOYSA-N 0.000 description 1
- QWOAHPFLIWLYAL-UHFFFAOYSA-N 2,4-dimethyl-5-oxo-8H-quinoline-6-carboxylic acid Chemical compound Cc1cc(C)c2C(=O)C(=CCc2n1)C(O)=O QWOAHPFLIWLYAL-UHFFFAOYSA-N 0.000 description 1
- LVYLCBNXHHHPSB-UHFFFAOYSA-N 2-hydroxyethyl salicylate Chemical compound OCCOC(=O)C1=CC=CC=C1O LVYLCBNXHHHPSB-UHFFFAOYSA-N 0.000 description 1
- YCLWEYIBFOLMEM-AGIMVQGUSA-N 4,5-dihydrocortisone Chemical compound C1C(=O)CC[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC21 YCLWEYIBFOLMEM-AGIMVQGUSA-N 0.000 description 1
- UPXRTVAIJMUAQR-UHFFFAOYSA-N 4-(9h-fluoren-9-ylmethoxycarbonylamino)-1-[(2-methylpropan-2-yl)oxycarbonyl]pyrrolidine-2-carboxylic acid Chemical compound C1C(C(O)=O)N(C(=O)OC(C)(C)C)CC1NC(=O)OCC1C2=CC=CC=C2C2=CC=CC=C21 UPXRTVAIJMUAQR-UHFFFAOYSA-N 0.000 description 1
- XZKIHKMTEMTJQX-UHFFFAOYSA-N 4-Nitrophenyl Phosphate Chemical compound OP(O)(=O)OC1=CC=C([N+]([O-])=O)C=C1 XZKIHKMTEMTJQX-UHFFFAOYSA-N 0.000 description 1
- TYJOQICPGZGYDT-UHFFFAOYSA-N 4-methylsulfonylbenzenesulfonyl chloride Chemical compound CS(=O)(=O)C1=CC=C(S(Cl)(=O)=O)C=C1 TYJOQICPGZGYDT-UHFFFAOYSA-N 0.000 description 1
- PJJGZPJJTHBVMX-UHFFFAOYSA-N 5,7-Dihydroxyisoflavone Chemical compound C=1C(O)=CC(O)=C(C2=O)C=1OC=C2C1=CC=CC=C1 PJJGZPJJTHBVMX-UHFFFAOYSA-N 0.000 description 1
- BSYNRYMUTXBXSQ-FOQJRBATSA-N 59096-14-9 Chemical compound CC(=O)OC1=CC=CC=C1[14C](O)=O BSYNRYMUTXBXSQ-FOQJRBATSA-N 0.000 description 1
- XBHBWNFJWIASRO-UHFFFAOYSA-N 6-fluoro-1-(4-fluorophenyl)-4-oxo-7-(1-piperazinyl)-3-quinolinecarboxylic acid Chemical compound C12=CC(N3CCNCC3)=C(F)C=C2C(=O)C(C(=O)O)=CN1C1=CC=C(F)C=C1 XBHBWNFJWIASRO-UHFFFAOYSA-N 0.000 description 1
- MPORYQCGWFQFLA-ONPDANIMSA-N 7-[(7s)-7-amino-5-azaspiro[2.4]heptan-5-yl]-8-chloro-6-fluoro-1-[(1r,2s)-2-fluorocyclopropyl]-4-oxoquinoline-3-carboxylic acid;trihydrate Chemical compound O.O.O.C([C@H]1N)N(C=2C(=C3C(C(C(C(O)=O)=CN3[C@H]3[C@H](C3)F)=O)=CC=2F)Cl)CC11CC1.C([C@H]1N)N(C=2C(=C3C(C(C(C(O)=O)=CN3[C@H]3[C@H](C3)F)=O)=CC=2F)Cl)CC11CC1 MPORYQCGWFQFLA-ONPDANIMSA-N 0.000 description 1
- ZYYSOFMPKMYKAJ-UHFFFAOYSA-N 7-methyl-4-oxo-1-propan-2-ylquinoline-3-carboxylic acid Chemical compound CC(C)n1cc(C(O)=O)c(=O)c2ccc(C)cc12 ZYYSOFMPKMYKAJ-UHFFFAOYSA-N 0.000 description 1
- RYVUQGFVQHXYKQ-UHFFFAOYSA-N 7-methyl-4-oxo-1h-quinoline-3-carboxylic acid Chemical compound OC1=C(C(O)=O)C=NC2=CC(C)=CC=C21 RYVUQGFVQHXYKQ-UHFFFAOYSA-N 0.000 description 1
- GSDSWSVVBLHKDQ-UHFFFAOYSA-N 9-fluoro-3-methyl-10-(4-methylpiperazin-1-yl)-7-oxo-2,3-dihydro-7H-[1,4]oxazino[2,3,4-ij]quinoline-6-carboxylic acid Chemical compound FC1=CC(C(C(C(O)=O)=C2)=O)=C3N2C(C)COC3=C1N1CCN(C)CC1 GSDSWSVVBLHKDQ-UHFFFAOYSA-N 0.000 description 1
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 1
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 1
- RMMXTBMQSGEXHJ-UHFFFAOYSA-N Aminophenazone Chemical compound O=C1C(N(C)C)=C(C)N(C)N1C1=CC=CC=C1 RMMXTBMQSGEXHJ-UHFFFAOYSA-N 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
- 101001050984 Apple stem grooving virus (strain Korea) Putative movement protein Proteins 0.000 description 1
- 101001050983 Apple stem grooving virus (strain P-209) Probable movement protein Proteins 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 1
- 238000011725 BALB/c mouse Methods 0.000 description 1
- KPYSYYIEGFHWSV-UHFFFAOYSA-N Baclofen Chemical compound OC(=O)CC(CN)C1=CC=C(Cl)C=C1 KPYSYYIEGFHWSV-UHFFFAOYSA-N 0.000 description 1
- 108020000946 Bacterial DNA Proteins 0.000 description 1
- 208000035143 Bacterial infection Diseases 0.000 description 1
- MGQLHRYJBWGORO-LLVKDONJSA-N Balofloxacin Chemical compound C1[C@H](NC)CCCN1C1=C(F)C=C2C(=O)C(C(O)=O)=CN(C3CC3)C2=C1OC MGQLHRYJBWGORO-LLVKDONJSA-N 0.000 description 1
- SPFYMRJSYKOXGV-UHFFFAOYSA-N Baytril Chemical compound C1CN(CC)CCN1C(C(=C1)F)=CC2=C1C(=O)C(C(O)=O)=CN2C1CC1 SPFYMRJSYKOXGV-UHFFFAOYSA-N 0.000 description 1
- MNIPYSSQXLZQLJ-UHFFFAOYSA-N Biofenac Chemical compound OC(=O)COC(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl MNIPYSSQXLZQLJ-UHFFFAOYSA-N 0.000 description 1
- 239000005885 Buprofezin Substances 0.000 description 1
- 229940124638 COX inhibitor Drugs 0.000 description 1
- UDKCHVLMFQVBAA-UHFFFAOYSA-M Choline salicylate Chemical compound C[N+](C)(C)CCO.OC1=CC=CC=C1C([O-])=O UDKCHVLMFQVBAA-UHFFFAOYSA-M 0.000 description 1
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 1
- 102000003844 DNA helicases Human genes 0.000 description 1
- QMLVECGLEOSESV-RYUDHWBXSA-N Danofloxacin Chemical compound C([C@@H]1C[C@H]2CN1C)N2C(C(=CC=1C(=O)C(C(O)=O)=C2)F)=CC=1N2C1CC1 QMLVECGLEOSESV-RYUDHWBXSA-N 0.000 description 1
- YZCKVEUIGOORGS-OUBTZVSYSA-N Deuterium Chemical compound [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 description 1
- URJQOOISAKEBKW-UHFFFAOYSA-N Emorfazone Chemical compound C1=NN(C)C(=O)C(OCC)=C1N1CCOCC1 URJQOOISAKEBKW-UHFFFAOYSA-N 0.000 description 1
- 241000792859 Enema Species 0.000 description 1
- 241000283074 Equus asinus Species 0.000 description 1
- 108010008165 Etanercept Proteins 0.000 description 1
- PIICEJLVQHRZGT-UHFFFAOYSA-N Ethylenediamine Chemical compound NCCN PIICEJLVQHRZGT-UHFFFAOYSA-N 0.000 description 1
- 239000005780 Fluazinam Substances 0.000 description 1
- 102000003676 Glucocorticoid Receptors Human genes 0.000 description 1
- 108090000079 Glucocorticoid Receptors Proteins 0.000 description 1
- AIJTTZAVMXIJGM-UHFFFAOYSA-N Grepafloxacin Chemical compound C1CNC(C)CN1C(C(=C1C)F)=CC2=C1C(=O)C(C(O)=O)=CN2C1CC1 AIJTTZAVMXIJGM-UHFFFAOYSA-N 0.000 description 1
- 102100031573 Hematopoietic progenitor cell antigen CD34 Human genes 0.000 description 1
- 102100029100 Hematopoietic prostaglandin D synthase Human genes 0.000 description 1
- 101000777663 Homo sapiens Hematopoietic progenitor cell antigen CD34 Proteins 0.000 description 1
- 101000988802 Homo sapiens Hematopoietic prostaglandin D synthase Proteins 0.000 description 1
- 101000716729 Homo sapiens Kit ligand Proteins 0.000 description 1
- HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 108010002386 Interleukin-3 Proteins 0.000 description 1
- 108090001005 Interleukin-6 Proteins 0.000 description 1
- YQEZLKZALYSWHR-UHFFFAOYSA-N Ketamine Chemical compound C=1C=CC=C(Cl)C=1C1(NC)CCCCC1=O YQEZLKZALYSWHR-UHFFFAOYSA-N 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 1
- HXEACLLIILLPRG-YFKPBYRVSA-N L-pipecolic acid Chemical compound [O-]C(=O)[C@@H]1CCCC[NH2+]1 HXEACLLIILLPRG-YFKPBYRVSA-N 0.000 description 1
- XAGMUUZPGZWTRP-ZETCQYMHSA-N LSM-5745 Chemical compound C([C@@H](N1C2=C(C(C(C(O)=O)=C1)=O)C=C1F)C)OC2=C1C1(N)CC1 XAGMUUZPGZWTRP-ZETCQYMHSA-N 0.000 description 1
- BPFYOAJNDMUVBL-UHFFFAOYSA-N LSM-5799 Chemical compound C1CN(C)CCN1C1=C(F)C=C2C(=O)C(C(O)=O)=CN3N(C)COC1=C32 BPFYOAJNDMUVBL-UHFFFAOYSA-N 0.000 description 1
- GSDSWSVVBLHKDQ-JTQLQIEISA-N Levofloxacin Chemical compound C([C@@H](N1C2=C(C(C(C(O)=O)=C1)=O)C=C1F)C)OC2=C1N1CCN(C)CC1 GSDSWSVVBLHKDQ-JTQLQIEISA-N 0.000 description 1
- HZQDCMWJEBCWBR-UUOKFMHZSA-N Mizoribine Chemical compound OC1=C(C(=O)N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 HZQDCMWJEBCWBR-UUOKFMHZSA-N 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- HOKKHZGPKSLGJE-GSVOUGTGSA-N N-Methyl-D-aspartic acid Chemical compound CN[C@@H](C(O)=O)CC(O)=O HOKKHZGPKSLGJE-GSVOUGTGSA-N 0.000 description 1
- QIPQASLPWJVQMH-DTORHVGOSA-N Orbifloxacin Chemical compound C1[C@@H](C)N[C@@H](C)CN1C1=C(F)C(F)=C2C(=O)C(C(O)=O)=CN(C3CC3)C2=C1F QIPQASLPWJVQMH-DTORHVGOSA-N 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- 206010034133 Pathogen resistance Diseases 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- TVQZAMVBTVNYLA-UHFFFAOYSA-N Pranoprofen Chemical compound C1=CC=C2CC3=CC(C(C(O)=O)C)=CC=C3OC2=N1 TVQZAMVBTVNYLA-UHFFFAOYSA-N 0.000 description 1
- 102000016971 Proto-Oncogene Proteins c-kit Human genes 0.000 description 1
- 108010014608 Proto-Oncogene Proteins c-kit Proteins 0.000 description 1
- PWNMXPDKBYZCOO-UHFFFAOYSA-N Prulifloxacin Chemical compound C1=C2N3C(C)SC3=C(C(O)=O)C(=O)C2=CC(F)=C1N(CC1)CCN1CC=1OC(=O)OC=1C PWNMXPDKBYZCOO-UHFFFAOYSA-N 0.000 description 1
- NJCJBUHJQLFDSW-UHFFFAOYSA-N Rufloxacin Chemical compound C1CN(C)CCN1C1=C(F)C=C2C(=O)C(C(O)=O)=CN3CCSC1=C32 NJCJBUHJQLFDSW-UHFFFAOYSA-N 0.000 description 1
- SKZKKFZAGNVIMN-UHFFFAOYSA-N Salicilamide Chemical compound NC(=O)C1=CC=CC=C1O SKZKKFZAGNVIMN-UHFFFAOYSA-N 0.000 description 1
- 206010070834 Sensitisation Diseases 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 229960004420 aceclofenac Drugs 0.000 description 1
- 229960004892 acemetacin Drugs 0.000 description 1
- FSQKKOOTNAMONP-UHFFFAOYSA-N acemetacin Chemical compound CC1=C(CC(=O)OCC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 FSQKKOOTNAMONP-UHFFFAOYSA-N 0.000 description 1
- 229960001138 acetylsalicylic acid Drugs 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 206010064930 age-related macular degeneration Diseases 0.000 description 1
- 229960005142 alclofenac Drugs 0.000 description 1
- ARHWPKZXBHOEEE-UHFFFAOYSA-N alclofenac Chemical compound OC(=O)CC1=CC=C(OCC=C)C(Cl)=C1 ARHWPKZXBHOEEE-UHFFFAOYSA-N 0.000 description 1
- 229960004663 alminoprofen Drugs 0.000 description 1
- FPHLBGOJWPEVME-UHFFFAOYSA-N alminoprofen Chemical compound OC(=O)C(C)C1=CC=C(NCC(C)=C)C=C1 FPHLBGOJWPEVME-UHFFFAOYSA-N 0.000 description 1
- SOYCMDCMZDHQFP-UHFFFAOYSA-N amfenac Chemical compound NC1=C(CC(O)=O)C=CC=C1C(=O)C1=CC=CC=C1 SOYCMDCMZDHQFP-UHFFFAOYSA-N 0.000 description 1
- 229950008930 amfenac Drugs 0.000 description 1
- 229960000212 aminophenazone Drugs 0.000 description 1
- 229940035676 analgesics Drugs 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 239000000730 antalgic agent Substances 0.000 description 1
- 229940121363 anti-inflammatory agent Drugs 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 229940124599 anti-inflammatory drug Drugs 0.000 description 1
- 230000000845 anti-microbial effect Effects 0.000 description 1
- 230000001022 anti-muscarinic effect Effects 0.000 description 1
- 229940125681 anticonvulsant agent Drugs 0.000 description 1
- 239000001961 anticonvulsive agent Substances 0.000 description 1
- 239000000935 antidepressant agent Substances 0.000 description 1
- 229940005513 antidepressants Drugs 0.000 description 1
- 229950004064 antrafenine Drugs 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 229940009100 aurothiomalate Drugs 0.000 description 1
- XJHSMFDIQHVMCY-UHFFFAOYSA-M aurothiomalic acid Chemical compound OC(=O)CC(S[Au])C(O)=O XJHSMFDIQHVMCY-UHFFFAOYSA-M 0.000 description 1
- 229960001671 azapropazone Drugs 0.000 description 1
- WOIIIUDZSOLAIW-NSHDSACASA-N azapropazone Chemical compound C1=C(C)C=C2N3C(=O)[C@H](CC=C)C(=O)N3C(N(C)C)=NC2=C1 WOIIIUDZSOLAIW-NSHDSACASA-N 0.000 description 1
- 229960002170 azathioprine Drugs 0.000 description 1
- LMEKQMALGUDUQG-UHFFFAOYSA-N azathioprine Chemical compound CN1C=NC([N+]([O-])=O)=C1SC1=NC=NC2=C1NC=N2 LMEKQMALGUDUQG-UHFFFAOYSA-N 0.000 description 1
- 229960000794 baclofen Drugs 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 208000022362 bacterial infectious disease Diseases 0.000 description 1
- 244000052616 bacterial pathogen Species 0.000 description 1
- 239000003899 bactericide agent Substances 0.000 description 1
- 229950000805 balofloxacin Drugs 0.000 description 1
- 229960004277 benorilate Drugs 0.000 description 1
- FEJKLNWAOXSSNR-UHFFFAOYSA-N benorilate Chemical compound C1=CC(NC(=O)C)=CC=C1OC(=O)C1=CC=CC=C1OC(C)=O FEJKLNWAOXSSNR-UHFFFAOYSA-N 0.000 description 1
- 229960005430 benoxaprofen Drugs 0.000 description 1
- 229960000333 benzydamine Drugs 0.000 description 1
- QRZAKQDHEVVFRX-UHFFFAOYSA-N biphenyl-4-ylacetic acid Chemical compound C1=CC(CC(=O)O)=CC=C1C1=CC=CC=C1 QRZAKQDHEVVFRX-UHFFFAOYSA-N 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- MOYGZHXDRJNJEP-UHFFFAOYSA-N buclizine Chemical compound C1=CC(C(C)(C)C)=CC=C1CN1CCN(C(C=2C=CC=CC=2)C=2C=CC(Cl)=CC=2)CC1 MOYGZHXDRJNJEP-UHFFFAOYSA-N 0.000 description 1
- 229960001705 buclizine Drugs 0.000 description 1
- PRLVTUNWOQKEAI-VKAVYKQESA-N buprofezin Chemical compound O=C1N(C(C)C)\C(=N\C(C)(C)C)SCN1C1=CC=CC=C1 PRLVTUNWOQKEAI-VKAVYKQESA-N 0.000 description 1
- 229960002962 butenafine Drugs 0.000 description 1
- ABJKWBDEJIDSJZ-UHFFFAOYSA-N butenafine Chemical compound C=1C=CC2=CC=CC=C2C=1CN(C)CC1=CC=C(C(C)(C)C)C=C1 ABJKWBDEJIDSJZ-UHFFFAOYSA-N 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 229960000590 celecoxib Drugs 0.000 description 1
- RZEKVGVHFLEQIL-UHFFFAOYSA-N celecoxib Chemical compound C1=CC(C)=CC=C1C1=CC(C(F)(F)F)=NN1C1=CC=C(S(N)(=O)=O)C=C1 RZEKVGVHFLEQIL-UHFFFAOYSA-N 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 230000000973 chemotherapeutic effect Effects 0.000 description 1
- 229960002688 choline salicylate Drugs 0.000 description 1
- 229960003405 ciprofloxacin Drugs 0.000 description 1
- QGPKADBNRMWEQR-UHFFFAOYSA-N clinafloxacin Chemical compound C1C(N)CCN1C1=C(F)C=C2C(=O)C(C(O)=O)=CN(C3CC3)C2=C1Cl QGPKADBNRMWEQR-UHFFFAOYSA-N 0.000 description 1
- 229950001320 clinafloxacin Drugs 0.000 description 1
- 229950001647 clometacin Drugs 0.000 description 1
- DGMZLCLHHVYDIS-UHFFFAOYSA-N clometacin Chemical compound CC=1N(CC(O)=O)C2=CC(OC)=CC=C2C=1C(=O)C1=CC=C(Cl)C=C1 DGMZLCLHHVYDIS-UHFFFAOYSA-N 0.000 description 1
- 239000003636 conditioned culture medium Substances 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 229960004397 cyclophosphamide Drugs 0.000 description 1
- 229960004385 danofloxacin Drugs 0.000 description 1
- 229960001145 deflazacort Drugs 0.000 description 1
- FBHSPRKOSMHSIF-GRMWVWQJSA-N deflazacort Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@@H]2[C@@H]1[C@@H]1C[C@H]3OC(C)=N[C@@]3(C(=O)COC(=O)C)[C@@]1(C)C[C@@H]2O FBHSPRKOSMHSIF-GRMWVWQJSA-N 0.000 description 1
- DYDCPNMLZGFQTM-UHFFFAOYSA-N delafloxacin Chemical compound C1=C(F)C(N)=NC(N2C3=C(Cl)C(N4CC(O)C4)=C(F)C=C3C(=O)C(C(O)=O)=C2)=C1F DYDCPNMLZGFQTM-UHFFFAOYSA-N 0.000 description 1
- 229950006412 delafloxacin Drugs 0.000 description 1
- 230000030609 dephosphorylation Effects 0.000 description 1
- 238000006209 dephosphorylation reaction Methods 0.000 description 1
- 210000004207 dermis Anatomy 0.000 description 1
- 230000001066 destructive effect Effects 0.000 description 1
- 229910052805 deuterium Inorganic materials 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 229960002783 dexketoprofen Drugs 0.000 description 1
- DKYWVDODHFEZIM-NSHDSACASA-N dexketoprofen Chemical compound OC(=O)[C@@H](C)C1=CC=CC(C(=O)C=2C=CC=CC=2)=C1 DKYWVDODHFEZIM-NSHDSACASA-N 0.000 description 1
- HPNMFZURTQLUMO-UHFFFAOYSA-N diethylamine Chemical compound CCNCC HPNMFZURTQLUMO-UHFFFAOYSA-N 0.000 description 1
- 229950001733 difloxacin Drugs 0.000 description 1
- NOCJXYPHIIZEHN-UHFFFAOYSA-N difloxacin Chemical compound C1CN(C)CCN1C(C(=C1)F)=CC2=C1C(=O)C(C(O)=O)=CN2C1=CC=C(F)C=C1 NOCJXYPHIIZEHN-UHFFFAOYSA-N 0.000 description 1
- 229960000616 diflunisal Drugs 0.000 description 1
- HUPFGZXOMWLGNK-UHFFFAOYSA-N diflunisal Chemical compound C1=C(O)C(C(=O)O)=CC(C=2C(=CC(F)=CC=2)F)=C1 HUPFGZXOMWLGNK-UHFFFAOYSA-N 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 229960003722 doxycycline Drugs 0.000 description 1
- XQTWDDCIUJNLTR-CVHRZJFOSA-N doxycycline monohydrate Chemical compound O.O=C1C2=C(O)C=CC=C2[C@H](C)[C@@H]2C1=C(O)[C@]1(O)C(=O)C(C(N)=O)=C(O)[C@@H](N(C)C)[C@@H]1[C@H]2O XQTWDDCIUJNLTR-CVHRZJFOSA-N 0.000 description 1
- 229950010243 emorfazone Drugs 0.000 description 1
- 239000007920 enema Substances 0.000 description 1
- 229940079360 enema for constipation Drugs 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 229960002549 enoxacin Drugs 0.000 description 1
- IDYZIJYBMGIQMJ-UHFFFAOYSA-N enoxacin Chemical compound N1=C2N(CC)C=C(C(O)=O)C(=O)C2=CC(F)=C1N1CCNCC1 IDYZIJYBMGIQMJ-UHFFFAOYSA-N 0.000 description 1
- 229960000740 enrofloxacin Drugs 0.000 description 1
- 229960000403 etanercept Drugs 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 229960005293 etodolac Drugs 0.000 description 1
- XFBVBWWRPKNWHW-UHFFFAOYSA-N etodolac Chemical compound C1COC(CC)(CC(O)=O)C2=N[C]3C(CC)=CC=CC3=C21 XFBVBWWRPKNWHW-UHFFFAOYSA-N 0.000 description 1
- 230000005713 exacerbation Effects 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 229960000192 felbinac Drugs 0.000 description 1
- 229960001395 fenbufen Drugs 0.000 description 1
- ZPAKPRAICRBAOD-UHFFFAOYSA-N fenbufen Chemical compound C1=CC(C(=O)CCC(=O)O)=CC=C1C1=CC=CC=C1 ZPAKPRAICRBAOD-UHFFFAOYSA-N 0.000 description 1
- 229960003306 fleroxacin Drugs 0.000 description 1
- XBJBPGROQZJDOJ-UHFFFAOYSA-N fleroxacin Chemical compound C1CN(C)CCN1C1=C(F)C=C2C(=O)C(C(O)=O)=CN(CCF)C2=C1F XBJBPGROQZJDOJ-UHFFFAOYSA-N 0.000 description 1
- UZCGKGPEKUCDTF-UHFFFAOYSA-N fluazinam Chemical compound [O-][N+](=O)C1=CC(C(F)(F)F)=C(Cl)C([N+]([O-])=O)=C1NC1=NC=C(C(F)(F)F)C=C1Cl UZCGKGPEKUCDTF-UHFFFAOYSA-N 0.000 description 1
- 229960002011 fludrocortisone Drugs 0.000 description 1
- AAXVEMMRQDVLJB-BULBTXNYSA-N fludrocortisone Chemical compound O=C1CC[C@]2(C)[C@@]3(F)[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 AAXVEMMRQDVLJB-BULBTXNYSA-N 0.000 description 1
- 229960000676 flunisolide Drugs 0.000 description 1
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 1
- 239000006260 foam Substances 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 239000012737 fresh medium Substances 0.000 description 1
- 230000002538 fungal effect Effects 0.000 description 1
- 229960002870 gabapentin Drugs 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 229960003170 gemifloxacin Drugs 0.000 description 1
- ZRCVYEYHRGVLOC-HYARGMPZSA-N gemifloxacin Chemical compound C1C(CN)C(=N/OC)/CN1C(C(=C1)F)=NC2=C1C(=O)C(C(O)=O)=CN2C1CC1 ZRCVYEYHRGVLOC-HYARGMPZSA-N 0.000 description 1
- GWOFUCIGLDBNKM-UHFFFAOYSA-N glafenine Chemical compound OCC(O)COC(=O)C1=CC=CC=C1NC1=CC=NC2=CC(Cl)=CC=C12 GWOFUCIGLDBNKM-UHFFFAOYSA-N 0.000 description 1
- 229960001650 glafenine Drugs 0.000 description 1
- 229960002389 glycol salicylate Drugs 0.000 description 1
- 229960000642 grepafloxacin Drugs 0.000 description 1
- 125000000623 heterocyclic group Chemical group 0.000 description 1
- 102000055151 human KITLG Human genes 0.000 description 1
- 229960001680 ibuprofen Drugs 0.000 description 1
- 229960003444 immunosuppressant agent Drugs 0.000 description 1
- 229940125721 immunosuppressive agent Drugs 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 229960000905 indomethacin Drugs 0.000 description 1
- 229960004187 indoprofen Drugs 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 229960000598 infliximab Drugs 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 229960003299 ketamine Drugs 0.000 description 1
- 229960004184 ketamine hydrochloride Drugs 0.000 description 1
- DKYWVDODHFEZIM-UHFFFAOYSA-N ketoprofen Chemical compound OC(=O)C(C)C1=CC=CC(C(=O)C=2C=CC=CC=2)=C1 DKYWVDODHFEZIM-UHFFFAOYSA-N 0.000 description 1
- 229960000991 ketoprofen Drugs 0.000 description 1
- HXEACLLIILLPRG-RXMQYKEDSA-N l-pipecolic acid Natural products OC(=O)[C@H]1CCCCN1 HXEACLLIILLPRG-RXMQYKEDSA-N 0.000 description 1
- VHOGYURTWQBHIL-UHFFFAOYSA-N leflunomide Chemical compound O1N=CC(C(=O)NC=2C=CC(=CC=2)C(F)(F)F)=C1C VHOGYURTWQBHIL-UHFFFAOYSA-N 0.000 description 1
- 229960000681 leflunomide Drugs 0.000 description 1
- 229960003376 levofloxacin Drugs 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000003589 local anesthetic agent Substances 0.000 description 1
- 229960005015 local anesthetics Drugs 0.000 description 1
- 229960002422 lomefloxacin Drugs 0.000 description 1
- ZEKZLJVOYLTDKK-UHFFFAOYSA-N lomefloxacin Chemical compound FC1=C2N(CC)C=C(C(O)=O)C(=O)C2=CC(F)=C1N1CCNC(C)C1 ZEKZLJVOYLTDKK-UHFFFAOYSA-N 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 229960002373 loxoprofen Drugs 0.000 description 1
- BAZQYVYVKYOAGO-UHFFFAOYSA-M loxoprofen sodium hydrate Chemical compound O.O.[Na+].C1=CC(C(C([O-])=O)C)=CC=C1CC1C(=O)CCC1 BAZQYVYVKYOAGO-UHFFFAOYSA-M 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 229960002531 marbofloxacin Drugs 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 229960003464 mefenamic acid Drugs 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- DJGAAPFSPWAYTJ-UHFFFAOYSA-M metamizole sodium Chemical compound [Na+].O=C1C(N(CS([O-])(=O)=O)C)=C(C)N(C)N1C1=CC=CC=C1 DJGAAPFSPWAYTJ-UHFFFAOYSA-M 0.000 description 1
- 229960000485 methotrexate Drugs 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- HPNSFSBZBAHARI-UHFFFAOYSA-N micophenolic acid Natural products OC1=C(CC=C(C)CCC(O)=O)C(OC)=C(C)C2=C1C(=O)OC2 HPNSFSBZBAHARI-UHFFFAOYSA-N 0.000 description 1
- 238000000386 microscopy Methods 0.000 description 1
- 229960004023 minocycline Drugs 0.000 description 1
- DYKFCLLONBREIL-KVUCHLLUSA-N minocycline Chemical compound C([C@H]1C2)C3=C(N(C)C)C=CC(O)=C3C(=O)C1=C(O)[C@@]1(O)[C@@H]2[C@H](N(C)C)C(O)=C(C(N)=O)C1=O DYKFCLLONBREIL-KVUCHLLUSA-N 0.000 description 1
- 229950000844 mizoribine Drugs 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 125000002950 monocyclic group Chemical group 0.000 description 1
- 229960003702 moxifloxacin Drugs 0.000 description 1
- FABPRXSRWADJSP-MEDUHNTESA-N moxifloxacin Chemical compound COC1=C(N2C[C@H]3NCCC[C@H]3C2)C(F)=CC(C(C(C(O)=O)=C2)=O)=C1N2C1CC1 FABPRXSRWADJSP-MEDUHNTESA-N 0.000 description 1
- 239000003149 muscarinic antagonist Substances 0.000 description 1
- 229940035363 muscle relaxants Drugs 0.000 description 1
- 229940014456 mycophenolate Drugs 0.000 description 1
- HPNSFSBZBAHARI-RUDMXATFSA-N mycophenolic acid Chemical compound OC1=C(C\C=C(/C)CCC(O)=O)C(OC)=C(C)C2=C1C(=O)OC2 HPNSFSBZBAHARI-RUDMXATFSA-N 0.000 description 1
- 239000003158 myorelaxant agent Substances 0.000 description 1
- MZZFGPBSBMPMJK-UHFFFAOYSA-N n-(2-ethoxyphenyl)-2-hydroxypropanamide Chemical compound CCOC1=CC=CC=C1NC(=O)C(C)O MZZFGPBSBMPMJK-UHFFFAOYSA-N 0.000 description 1
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 229960003808 nadifloxacin Drugs 0.000 description 1
- JYJTVFIEFKZWCJ-UHFFFAOYSA-N nadifloxacin Chemical compound FC1=CC(C(C(C(O)=O)=C2)=O)=C3N2C(C)CCC3=C1N1CCC(O)CC1 JYJTVFIEFKZWCJ-UHFFFAOYSA-N 0.000 description 1
- 230000003533 narcotic effect Effects 0.000 description 1
- 208000004296 neuralgia Diseases 0.000 description 1
- 208000021722 neuropathic pain Diseases 0.000 description 1
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 1
- 230000000631 nonopiate Effects 0.000 description 1
- 229960001180 norfloxacin Drugs 0.000 description 1
- OGJPXUAPXNRGGI-UHFFFAOYSA-N norfloxacin Chemical compound C1=C2N(CC)C=C(C(O)=O)C(=O)C2=CC(F)=C1N1CCNCC1 OGJPXUAPXNRGGI-UHFFFAOYSA-N 0.000 description 1
- 229960001699 ofloxacin Drugs 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 229940127240 opiate Drugs 0.000 description 1
- 239000008203 oral pharmaceutical composition Substances 0.000 description 1
- 229960004780 orbifloxacin Drugs 0.000 description 1
- 239000001301 oxygen Chemical group 0.000 description 1
- 229960005489 paracetamol Drugs 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 229960002625 pazufloxacin Drugs 0.000 description 1
- 229960004236 pefloxacin Drugs 0.000 description 1
- FHFYDNQZQSQIAI-UHFFFAOYSA-N pefloxacin Chemical compound C1=C2N(CC)C=C(C(O)=O)C(=O)C2=CC(F)=C1N1CCN(C)CC1 FHFYDNQZQSQIAI-UHFFFAOYSA-N 0.000 description 1
- 229960001639 penicillamine Drugs 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 229960003893 phenacetin Drugs 0.000 description 1
- 229960001732 pipemidic acid Drugs 0.000 description 1
- JOHZPMXAZQZXHR-UHFFFAOYSA-N pipemidic acid Chemical compound N1=C2N(CC)C=C(C(O)=O)C(=O)C2=CN=C1N1CCNCC1 JOHZPMXAZQZXHR-UHFFFAOYSA-N 0.000 description 1
- 229960002292 piperacillin Drugs 0.000 description 1
- WCMIIGXFCMNQDS-IDYPWDAWSA-M piperacillin sodium Chemical compound [Na+].O=C1C(=O)N(CC)CCN1C(=O)N[C@H](C=1C=CC=CC=1)C(=O)N[C@@H]1C(=O)N2[C@@H](C([O-])=O)C(C)(C)S[C@@H]21 WCMIIGXFCMNQDS-IDYPWDAWSA-M 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 229960003101 pranoprofen Drugs 0.000 description 1
- 229960004618 prednisone Drugs 0.000 description 1
- XOFYZVNMUHMLCC-ZPOLXVRWSA-N prednisone Chemical compound O=C1C=C[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 XOFYZVNMUHMLCC-ZPOLXVRWSA-N 0.000 description 1
- 229940002612 prodrug Drugs 0.000 description 1
- 239000000651 prodrug Substances 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 150000003180 prostaglandins Chemical class 0.000 description 1
- 229960001224 prulifloxacin Drugs 0.000 description 1
- MIXMJCQRHVAJIO-TZHJZOAOSA-N qk4dys664x Chemical compound O.C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@@H]1[C@@H]2[C@@H]2C[C@H]3OC(C)(C)O[C@@]3(C(=O)CO)[C@@]2(C)C[C@@H]1O.C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@@H]1[C@@H]2[C@@H]2C[C@H]3OC(C)(C)O[C@@]3(C(=O)CO)[C@@]2(C)C[C@@H]1O MIXMJCQRHVAJIO-TZHJZOAOSA-N 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 238000012827 research and development Methods 0.000 description 1
- RZJQGNCSTQAWON-UHFFFAOYSA-N rofecoxib Chemical compound C1=CC(S(=O)(=O)C)=CC=C1C1=C(C=2C=CC=CC=2)C(=O)OC1 RZJQGNCSTQAWON-UHFFFAOYSA-N 0.000 description 1
- 229960000371 rofecoxib Drugs 0.000 description 1
- 229940069575 rompun Drugs 0.000 description 1
- 229960005224 roxithromycin Drugs 0.000 description 1
- 229960004062 rufloxacin Drugs 0.000 description 1
- 229960000581 salicylamide Drugs 0.000 description 1
- 229960000953 salsalate Drugs 0.000 description 1
- 229950007734 sarafloxacin Drugs 0.000 description 1
- 230000008313 sensitization Effects 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 239000012679 serum free medium Substances 0.000 description 1
- 229960003177 sitafloxacin Drugs 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 229960004954 sparfloxacin Drugs 0.000 description 1
- DZZWHBIBMUVIIW-DTORHVGOSA-N sparfloxacin Chemical compound C1[C@@H](C)N[C@@H](C)CN1C1=C(F)C(N)=C2C(=O)C(C(O)=O)=CN(C3CC3)C2=C1F DZZWHBIBMUVIIW-DTORHVGOSA-N 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 238000005507 spraying Methods 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 239000012086 standard solution Substances 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 210000000130 stem cell Anatomy 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000011593 sulfur Chemical group 0.000 description 1
- MLKXDPUZXIRXEP-MFOYZWKCSA-N sulindac Chemical compound CC1=C(CC(O)=O)C2=CC(F)=CC=C2\C1=C/C1=CC=C(S(C)=O)C=C1 MLKXDPUZXIRXEP-MFOYZWKCSA-N 0.000 description 1
- 229960000894 sulindac Drugs 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 229960004492 suprofen Drugs 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 238000007910 systemic administration Methods 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 229960004576 temafloxacin Drugs 0.000 description 1
- 238000010257 thawing Methods 0.000 description 1
- HTJXMOGUGMSZOG-UHFFFAOYSA-N tiaramide Chemical compound C1CN(CCO)CCN1C(=O)CN1C(=O)SC2=CC=C(Cl)C=C21 HTJXMOGUGMSZOG-UHFFFAOYSA-N 0.000 description 1
- 229950010302 tiaramide Drugs 0.000 description 1
- 229960002905 tolfenamic acid Drugs 0.000 description 1
- YEZNLOUZAIOMLT-UHFFFAOYSA-N tolfenamic acid Chemical compound CC1=C(Cl)C=CC=C1NC1=CC=CC=C1C(O)=O YEZNLOUZAIOMLT-UHFFFAOYSA-N 0.000 description 1
- 210000003437 trachea Anatomy 0.000 description 1
- 239000003204 tranquilizing agent Substances 0.000 description 1
- 230000002936 tranquilizing effect Effects 0.000 description 1
- 229960005294 triamcinolone Drugs 0.000 description 1
- GFNANZIMVAIWHM-OBYCQNJPSA-N triamcinolone Chemical compound O=C1C=C[C@]2(C)[C@@]3(F)[C@@H](O)C[C@](C)([C@@]([C@H](O)C4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 GFNANZIMVAIWHM-OBYCQNJPSA-N 0.000 description 1
- 230000001960 triggered effect Effects 0.000 description 1
- 229960000497 trovafloxacin Drugs 0.000 description 1
- WVPSKSLAZQPAKQ-CDMJZVDBSA-N trovafloxacin Chemical compound C([C@H]1[C@@H]([C@H]1C1)N)N1C(C(=CC=1C(=O)C(C(O)=O)=C2)F)=NC=1N2C1=CC=C(F)C=C1F WVPSKSLAZQPAKQ-CDMJZVDBSA-N 0.000 description 1
- 208000019206 urinary tract infection Diseases 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
- 229960004175 xylazine hydrochloride Drugs 0.000 description 1
- QYEFBJRXKKSABU-UHFFFAOYSA-N xylazine hydrochloride Chemical compound Cl.CC1=CC=CC(C)=C1NC1=NCCCS1 QYEFBJRXKKSABU-UHFFFAOYSA-N 0.000 description 1
- 229960003414 zomepirac Drugs 0.000 description 1
- ZXVNMYWKKDOREA-UHFFFAOYSA-N zomepirac Chemical compound C1=C(CC(O)=O)N(C)C(C(=O)C=2C=CC(Cl)=CC=2)=C1C ZXVNMYWKKDOREA-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/473—Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4741—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having oxygen as a ring hetero atom, e.g. tubocuraran derivatives, noscapine, bicuculline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0043—Nose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Physical Education & Sports Medicine (AREA)
- Rheumatology (AREA)
- Immunology (AREA)
- Pulmonology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Diabetes (AREA)
- Dermatology (AREA)
- Communicable Diseases (AREA)
- Otolaryngology (AREA)
- Urology & Nephrology (AREA)
- Ophthalmology & Optometry (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Neurology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pain & Pain Management (AREA)
- Obesity (AREA)
- Cardiology (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Biomedical Technology (AREA)
- Virology (AREA)
- Neurosurgery (AREA)
- Transplantation (AREA)
Abstract
本发明提供了用于治疗炎症性病症的萘啶酸和萘啶酸类似物。
Description
发明领域
本发明涉及萘啶酸和类似物用于治疗炎症性病症的用途。
发明背景
免疫引发的炎症性事件是许多慢性炎症性疾病的重要原因,其中长时间的炎症可引起组织破坏,并可导致被感染的器官大幅损伤并最终衰竭。在很多情况下,这些疾病的确切病因是未知的。这些疾病包括自身免疫疾病,其中,尽管不了解该疾病的确切致病特征,但是已知炎症性和组织破坏性方面是由对自身组织的不当的免疫应答引起的。涉及多个器官的病况包括例如系统性红斑狼疮(SLE)和硬皮病。其他类型的自身免疫疾病可涉及特定的组织或器官,例如肌肉骨骼组织(例如,风湿性关节炎、强直性脊柱炎)、胃肠道(例如,克罗恩氏病和溃疡性结肠炎)、中枢神经系统(例如,阿尔茨海默病、多发性硬化、运动神经元疾病、帕金森氏病和慢性疲劳综合症)、胰腺β细胞(例如,胰岛素依赖型糖尿病)、肾上腺(例如,爱迪生氏病)、肾脏(例如,古德帕斯彻氏综合症、IgA肾病、间质性肾炎)、外分泌腺(例如,干燥综合症和自身免疫性胰腺炎)、皮肤(例如,银屑病和特应性皮炎)和肺(例如哮喘)。
此外,存在某种程度上确定了病因的慢性炎症性疾病。这些疾病也可表现出大幅的组织/器官破坏并包括以下病况:例如骨关节炎、牙周病、糖尿病性肾病、慢性阻塞性肺病、动脉粥样硬化、移植物抗宿主病、慢性盆腔炎、子宫内膜异位、慢性肝炎和慢性肺结核。这些病况在发达国家和发展中国家中都是疾病的主要原因,并且在很多情况下通过目前的治疗方法不能有好地治疗。例如,皮肤结构的炎症(皮炎)是常见的一组病况,其包括酒糟鼻、寻常性痤疮、变应性接触性皮炎、血管性水肿、特应性皮炎、大疱性类天疱疮、皮肤药物反应、多形性红斑、红斑狼疮、光照性皮炎、银屑病、银屑病关节炎、硬皮病和荨麻疹。诸如哮喘、慢性阻塞性肺病(COPD)和特发性肺纤维化(IPF)的呼吸道疾病以及诸如克罗恩氏病和溃疡性结肠炎的胃肠道的炎症性疾病,也代表着人类疾病的重要原因。使用多种治疗方法来治疗这些疾病,其中的很多方法具有非常严重的副作用。
目前对炎症性引发的病况的治疗(若存在)包括中和抗体、细胞毒性、皮质类固醇、免疫抑制剂、抗组胺药和抗毒蕈碱药。这些治疗经常与不便的施用途径和严重的副作用有关,而导致依从性的问题。
亟需新型的有效且安全的治疗方法。
膜联蛋白-A1(脂皮质素-1)是36kDa蛋白质,其于20世纪70年代末被首次描述。膜联蛋白-A1在许多细胞类型中均有发现,并且已知其在调节外源性和内源性糖皮质激素的抗炎活性中起关键的作用。膜联蛋白-A1增强了类固醇的抗炎活性,并且在敲除膜联蛋白-A1的小鼠中类固醇对动物炎症模型是无效的,而膜联蛋白-A1自身对动物炎症模型是有效的(PerrettiM.和DalliJ.BritishJournalofPharmacology(2009)158,p936-946)。
非活性的膜联蛋白-A1通过糖皮质激素受体刺激的细胞核作用而在细胞内释放。所述膜联蛋白-A1被转位至细胞膜,在该处被蛋白激酶C磷酸化并作为抗炎蛋白释放。磷酸酶PP2A负责通过直接去磷酸化和使蛋白激酶C失活而使膜联蛋白-A1的抗炎活性失活(YazidS.等人PharmacologicalReports(2010)62,p511-517)。假定PP2A的抑制剂会提供强效的抗炎药物。
发明概述
本发明涉及萘啶酸和萘啶酸类似物在炎症性疾病的治疗中的用途。
意外地发现萘啶酸(I)和一些萘啶酸的类似物对治疗炎症性病况有效。
已发现了萘啶酸和一些类似物是磷酸酶PP2A的强效抑制剂,由此增强内源性膜联蛋白-A1的抗炎活性。由于萘啶酸通过肾途径快速排泄,并由此具有差的全身性药代动力学,因此是治疗泌尿系统感染最常用的抗生素。该试剂通常需要每日四次的通过口服途径施用的治疗来达到抗菌活性。
现已发现使用萘啶酸或萘啶酸类似物或其药物可接受的盐对治疗例如但不限于上文描述的那些炎症性疾病是有效的。
因此,根据本发明,萘啶酸和萘啶酸的类似物可用于炎症性疾病的治疗。
附图描述
图1示出了萘啶酸对人肥大细胞中净组胺释放%的抑制。
图2示出了萘啶酸对人肥大细胞中前列腺素D2释放的抑制。
图3示出了从人肥大细胞中膜联蛋白-A1的释放应答于增大的萘啶酸浓度。
图4示出了在哮喘的鼠模型中通过鼻内途径给予的萘啶酸对卵清蛋白诱发的BALF中嗜酸性粒细胞数的抑制。
图5示出了在卵清蛋白诱发的哮喘的鼠模型中萘啶酸对总BALF细胞数中嗜酸性粒细胞百分比的抑制。
发明详述
施用萘啶酸(I)、或萘啶酸药物可接受的盐用于一系列炎症性病况的治疗。
根据本发明的另一个方面,通式(II)的化合物可用于炎症性病况的治疗或预防
其中,
X和X1独立地表示CH或N;
X2表示C(R2)或N;
X4表示C(R4)或N;
R1为H、CF3、CONH2、CN、卤素、NH2、NH-烃基、烃基、环烃基或苯基,并任选地被一个或多个R6取代;其中R1可与R2形成环的部分;
R2为H、CF3、CONH2、CN、卤素、NH2、烃基、O-烃基或S-烃基;其中R2可与R1形成环的部分,其中该环为5元或6元的饱和或不饱和环,含有一个或多个选自C、N、S和O的原子;
R3为H、CF3、CONH2、CN、卤素、NH2、烃基、O-烃基、吡啶基、环烃基或杂环烃基,并任选地被一个或多个R6取代;其中R3可与R4形成环的部分;
R4为H、F或O-烃基;其中R4可与R3形成环的部分,其中该环为5元的饱和或不饱和环,含有一个或多个选自C、N、S和O的原子;
R5为H、F、Cl、烃基、O-烃基或NH2;
R6为F、烃基、NH2、NH-烃基、CH2NH2或OH。
任选地,R1、R2和R3独立地为CF3、CONH2、CN、卤素或NH2;
或其药物可接受的盐。
烃基指直链或支链的烃基,其含有1至10个碳原子,优选1至6个碳原子,更优选1至3个碳原子。优选的烃基实例为甲基、乙基、正丙基和异丙基。
环烃基指3至14个碳原子的且无环杂原子的饱和或部分饱和的环状基团,且含有单环或多环,所述多环包括稠环、桥环和螺环系统,其中所述环烃基任选地被一个或多个取代基取代,所述取代基选自CF3、CONH2、CN、卤素、NH2、NH-烃基、烃基、环烃基和苯基。
杂环烃基指含有1至14个碳原子和1至6个选自氮、硫或氧的杂原子的饱和或部分饱和的环状基团,并且包括单环和多环系统,所述多环系统包括稠环、桥环和螺环系统,其中所述环烃基任选地被一个或多个取代基取代,所述取代基选自CF3、CONH2、CN、卤素、NH2、NH-烃基、烃基、环烃基和苯基。优选的杂环烃基实例为哌啶、哌嗪和吡咯烷。
可被提及的本发明实施方案包括环烃基和/或杂环烃基未被取代的那些实施方案。
本领域的技术人员应意识到,本文提及的治疗延伸至确定病况的预防及治疗。
式(II)的化合物包括一些已知的喹诺酮抗生素。已知喹诺酮抗生素是广谱抗生素。其为化学治疗性杀菌药物,且其通过阻止细菌DNA解旋和复制来起作用。已知的喹诺酮抗生素包括:
第一代:西诺沙星、氟甲喹、恶喹酸、吡咯嘧啶酸、吡哌酸、罗索沙星。
第二代:环丙沙星、依诺沙星、氟罗沙星、洛美沙星、那氟沙星、诺氟沙星、氧氟沙星、培氟沙星、芦氟沙星。
第三代:巴洛沙星、格帕沙星、左氧氟沙星、帕珠沙星、司氟沙星、替马沙星、妥舒沙星。
第四代:克林沙星、加替沙星、吉米沙星、莫西沙星、西他沙星、曲伐沙星、普卢利沙星。
研发中:加雷沙星、德拉沙星。
兽用:达氟沙星、双氟沙星、恩诺沙星、依巴沙星、马波沙星、奥比沙星、沙氟沙星。
本发明中使用的式(II)的化合物包括(但不限于)上文描述的已知的喹诺酮抗生素和新颖的化合物,例如:
1-异丙基-7-甲基-4-氧-1,4-二氢喹啉-3-羧酸
1,5,7-三甲基-4-氧-1,4-二氢-1,8-萘啶-3-羧酸
2,4-二甲基-5-氧-5,8-二氢喹啉-6-羧酸
可以理解,本发明中使用的化合物包括盐,例如钠盐、钾盐、铵盐、乙二胺盐、精氨酸盐、二乙胺盐、哌嗪盐或N-甲基葡糖酰胺盐,而且还延伸至其代谢物和前体药物。最适合使用游离酸或盐。
本发明中使用的化合物或其药物可接受的盐可以是手性的,并且可以理解,本发明包括式(II)的任何非对映异构体和对映异构体。也可理解,本发明包括式(I)化合物和/或式(II)化合物的任何同位素衍生物。
为避免疑义,式(I)和式(II)的化合物可含有以其任何天然同位素形式或非天然同位素形式的所示出的原子。在这一方面,可提及的本发明的实施方案包括以下实施方案,其中:
a)式(I)的化合物和/或式(II)的化合物对于化合物的任何原子均未被同位素富集或被标记;以及
b)式(I)的化合物和/或式(II)的化合物对于化合物的一个或多个原子被同位素富集或被标记。
本文提及的“同位素衍生物”涉及这两种实施方案中的第二种实施方案。在本发明具体的实施方案中,式(I)的化合物和/或式(II)的化合物是用一个或多个稳定的同位素来同位素富集或标记的(针对化合物的一个或多个原子)。因此,可提及的本发明的化合物包括,例如,用一个或多个诸如氘等的原子同位素富集或标记的式(I)的化合物和/或式(II)的化合物。
优选的式(II)化合物的实例包括西诺沙星、氟甲喹、恶喹酸、吡咯嘧啶酸、哌啶酸和罗索沙星。
根据本发明,萘啶酸或式(II)的化合物、或其药物可接受的盐用于治疗炎症性疾病,其包括,但不专指:涉及多器官的自身免疫疾病,例如系统性红斑狼疮(SLE)和硬皮病;涉及特定组织或器官的自身免疫疾病,例如肌肉骨骼组织(例如,风湿性关节炎、强直性脊柱炎)、胃肠道(例如,克罗恩氏病和溃疡性结肠炎)、中枢神经系统(例如,阿尔茨海默病、多发性硬化、运动神经元疾病、帕金森氏病和慢性疲劳综合症)、胰腺β细胞(例如,胰岛素依赖型糖尿病)、肾上腺(例如,爱迪生氏病)、肾脏(例如,古德帕斯彻氏综合症、IgA肾病、间质性肾炎)、外分泌腺(例如,干燥综合症和自身免疫性胰腺炎)、皮肤(例如,银屑病和特应性皮炎)和肺(例如哮喘);慢性炎症性疾病,例如骨关节炎、牙周病、糖尿病性肾病、慢性阻塞性肺病、动脉粥样硬化、移植物抗宿主病、慢性盆腔炎、子宫内膜异位、慢性肝炎和慢性肺结核;IgE介导的(I型)超敏反应,例如鼻炎、哮喘、过敏反应和皮炎。皮炎病况包括光化性角化病、酒糟鼻、寻常性痤疮、变应性接触性皮炎、血管性水肿、特应性皮炎、大疱性类天疱疮、皮肤药物反应、多形性红斑、红斑狼疮、光照性皮炎、银屑病、银屑病关节炎、硬皮病和荨麻疹。也可治疗眼部病况,例如糖尿病视网膜病变、黄斑变性、脉络膜新生血管膜、囊状黄斑水肿、视网膜外膜、黄斑裂孔、干眼症、葡萄膜炎和结膜炎。尤其是萘啶酸或式(II)的类似物、或其药物可接受的盐用于治疗:慢性退行性疾病,例如风湿性关节炎、骨关节炎或骨质疏松症;慢性脱髓鞘疾病,例如多发性硬化;呼吸系统疾病,例如哮喘或慢性阻塞性肺病;炎症性肠病,例如溃疡性结肠炎或克罗恩氏病;皮肤病,例如银屑病、硬皮病或特应性皮炎;牙科疾病,例如牙周病或牙龈炎;糖尿病性肾病;狼疮性肾炎;IgA肾病;肾小球肾炎;系统性红斑狼疮;移植物抗宿主病;眼科病况,包括老年性黄斑变性、结膜炎、糖尿病视网膜病变、脉络膜新生血管膜、囊状黄斑水肿、视网膜外膜、黄斑裂孔、干眼症或葡萄膜炎。
在炎症性疾病的治疗中,通过局部施用来使用萘啶酸或萘啶酸的类似物是有利的。当局部使用时,本发明的化合物用于治疗炎症性疾病,其包括但不专指:涉及特定组织或器官的自身免疫疾病,例如胃肠道(例如,克罗恩氏病和溃疡性结肠炎)、皮肤(例如,银屑病和特应性皮炎)和肺;慢性炎症性疾病,例如慢性阻塞性肺病;以及超敏反应,例如鼻炎、哮喘、过敏反应和皮炎。皮炎病况包括光化性角化病、酒糟鼻、寻常性痤疮、变应性接触性皮炎、血管性水肿、特应性皮炎、大疱性类天疱疮、皮肤药物反应、多形性红斑、红斑狼疮、光照性皮炎、银屑病、银屑病关节炎、硬皮病和荨麻疹。特别地,本发明的化合物用于治疗:呼吸系统疾病,例如哮喘或慢性阻塞性肺病;炎症性肠病,例如溃疡性结肠炎或克罗恩氏病;皮肤病,例如银屑病、硬皮病或特应性皮炎;以及牙科疾病,例如牙龈炎和牙周病。
根据本发明,当患者也被施用另外的治疗剂时,可使用萘啶酸或式(II)的化合物或其盐,或其中提供本发明的化合物与另外的治疗剂的组合,其中所述治疗剂选自皮质类固醇(实例包括皮质醇、可的松、氢化可的松、二氢可的松、氟氢可的松、泼尼松、35泼尼松龙、地夫可特、氟尼缩松、伯克纳、甲基泼尼松龙、曲安西龙、倍他米松和地塞米松)、细胞毒性、改善病情的抗风湿药物(DMARD)(实例包括柳氮磺胺吡啶(azulfidine)、金硫代苹果酸盐、布西拉明、苯丁酸氮芥、环磷酰胺、来氟米特、甲氨蝶呤、咪唑立宾、青霉胺和柳氮磺胺吡啶(sulphasalazine))、免疫抑制剂(实例包括硫唑嘌呤、环孢素、霉酚酸酯)、COX抑制剂(实例包括醋氯芬酸、阿西美辛、阿氯酚酸(alcofenac)、阿明洛芬、阿洛普令、氨芬酸、氨基比林、安特非宁(antraphenine)、阿司匹林、阿扎丙宗、贝诺酯、苯恶洛芬、苄达明、布替布芬、塞来昔布、氯乙唤(chlorthenoxacine)、水杨酸胆碱、氯美辛(chlometacin)、右旋酮洛芬、双氯芬酸、二氟尼柳、依莫法宗、依匹唑、依托度酸、苯氯布宗、联苯乙酸、芬布芬、芬氯酸、氟比洛芬、格拉非宁、羟基乙基水杨酸酯、布洛芬、吲哚美辛、吲哚洛芬、酮洛芬、酮咯酸、乳酰基氨基苯乙醚、洛索洛芬、甲灭酸、安乃近、莫非保松、莫苯唑酸、萘丁美酮、萘普生、尼芬那宗、奥沙美辛、非那西丁、哌保松、普拉洛芬、异丙安替比林、普罗喹宗、罗非昔布、水杨酰胺、双水杨酸酯、舒林酸、舒洛芬、噻拉米特、替诺立定、托芬那酸、佐美酸)、中和抗体(实例包括依那西普和英夫利昔单抗)、抗生素(实例包括强力霉素和米诺环素)。
萘啶酸或式(II)的化合物、或其药物可接受的盐与用于疼痛治疗的药物组合使用常常是有利的。此类另外的药物可以是诸如巴氯芬的阿片或非阿片或诸如加巴喷丁的神经痛试剂。其他可使用的化合物包括:非类固醇抗炎药(例如,对乙酰氨基酚、乙酰水杨酸、萘普生)、麻醉镇痛药、局部麻醉药、NMDA拮抗剂、安定剂、抗惊厥药、抗痉挛药、抗抑郁药或肌肉松弛药。
本发明化合物的抗炎活性可通过实施例中描述的适当的体外试验或体内试验来表征。萘啶酸治疗均以剂量相关的形式对从IgE攻击的人肥大细胞中释放的组胺(实施例1)和PGD2(实施例2)进行抑制。此外,萘啶酸治疗以剂量相关的形式增大了膜联蛋白-A1的释放(实施例3)。
本发明化合物的抗炎活性与其抗菌活性无关,并且其抗炎效果可以在萘啶酸或式(II)的类似物的非抗菌浓度下观察。因此,根据本发明的另一方面,当萘啶酸或其类似物或其盐的量、剂量或浓度不具有实质的抗菌活性时,可以在炎症性病况的治疗或预防中使用萘啶酸(I)或式(II)的类似物、或其药物可接受的盐。在细菌感染不作为疾病组成部分的情况下,使用低于抗菌剂量的萘啶酸或式(II)的类似物、或其药物可接受的盐会避免不必要地暴露于可导致产生细菌抗药性的抗菌活性。
根据本发明另外的方面,萘啶酸或式(II)的化合物或其药物可接受的盐可用于增强糖皮质激素的抗炎作用。这种活性已通过使用适当的体外试验和体内试验被证实。因此,本发明的化合物与类固醇一同使用允许使用低于常规治疗剂量的、并因此无害的类固醇剂量,并具有大幅增强的抗炎活性。根据本发明,当患者也被施用一种或多种糖皮质激素时,可使用萘啶酸或式(II)的化合物、或其药物可接受的盐,或其中提供本发明的化合物与一种或多种糖皮质激素的组合。可在本发明中使用的糖皮质激素包括,但不限于,倍氯米松、倍他米松、布地奈德、可的松、地塞米松、氢化可的松、氟替卡松、甲泼尼松、莫美他松、帕拉米松和泼尼松龙。特别优选与塞米松、泼尼松龙、可的松、二氢可的松和氢化可的松的组合使用。
本发明的化合物可用作抗炎剂来治疗炎症性病况。在一些实例中,上文描述的疾病可伴随微生物感染。这种感染可以是真菌的、病毒的或细菌的。例如,哮喘和COPD的加重都可与肺部的并发感染有关。诸如特应性皮炎的真皮炎症性疾病也可与局部感染有关。本发明的化合物可用于治疗存在微生物感染或不存在微生物感染的炎症。存在微生物感染时,当患者也被施用抗生素时可使用本发明的化合物,或者本发明的化合物与抗生素组合施用。
可将本文描述的化合物配制用于以任何方便的方式施用,因此本发明也包括含萘啶酸或式(II)的类似物、或其药物可接受的盐一起的药物组合物,如果需要,则混合一种或多种药物可接受的稀释剂或载体。
可以使用任何适合的施用途径。例如,口服、局部、胃肠外、眼部、直肠、阴道、吸入式、口腔、舌下和鼻内递送途径的任何一种可以是适合的。
优选适于局部施用的药物组合物。可以使用任何适合的施用途径来对疾病位点进行活性剂的局部递送。特别优选适于对肺、皮肤、或胃肠道局部施用的组合物。各种类型的用于局部施用的制剂的实例包括软膏、洗剂、乳膏、凝胶、泡沫、喷雾剂、气雾剂、粉末、在吸入器或吹入器中使用的胶囊或药筒、滴剂、用于喷雾的溶液/悬浮液、栓剂、保留灌肠和阴道栓剂。
适于全身施用的萘啶酸或式(II)的类似物、或其药用盐的药物组合物作为本发明的另一个方面。优选口服的药物组合物。各种类型的用于口服施用的制剂的实例包括胶囊、片剂、微丸和液体组合物。也可以优选胃肠外的组合物。
活性剂的剂量取决于病况的性质和程度、患者的年龄和状况以及本领域技术人员已知的其他因素。典型的剂量为0.1mg至100mg,例如,取决于所涉及制剂的类型,活性成分为10至100mg。优选地,每天给予该剂量一至三次。本发明组合物中的活性剂的剂量可具有抗菌活性,或者其可低于抗菌剂量。优选地,存在的活性药物的量不具有实质的抗菌活性。抗菌活性意味着萘啶酸或式(II)的类似物的浓度对于在感染性病况中涉及的致病细菌的生长不具有临床相关的活性。对于敏感菌株,该浓度约小于1μg/ml。
组合物还可包含一种或多种类固醇和/或另外的治疗剂。通常,包含萘啶酸或式(II)的化合物或其药物可接受的盐、以及一种或多种类固醇的组合物含有该制剂的0.001%至5%wt/wt的类固醇。尽管特定的剂量取决于使用的特殊的类固醇,但是由于上文描述的本发明化合物的协同效应,优选以低于制剂的1%wt/wt的低于常规治疗剂量存在的类固醇。例如,当使用萘啶酸时,组合物中存在的萘啶酸为制剂的0.001%至5%wt/wt,且存在低于制剂的1%wt/wt的治疗剂量的类固醇。
一般通过多步合成路线来制备萘啶酸,该多步合成路线适于进行多种修改,以允许合成萘啶酸类似物,例如式(II)的类似物:
本发明中使用的式(II)的萘啶酸类似物可以由以下方案所示的多步合成步骤制备。
通过从通式(III)的二取代苯化合物开始的环化反应来进行所述合成:
其中R为技术人员已知的任何适合的基团。
然后通过Camps环化反应环化起始原料,以得到通式(IIIa)和(IIIb)的化合物:
然后可分离式(IIIa)的4-喹诺酮衍生物,并进一步反应以形成例如下式的4-喹诺酮衍生物:
7-甲基-4-氧-1,4-二氢喹啉-3-羧酸
式(II)的化合物或其药物可接受的盐的抗炎活性可以通过评估它们抑制组胺或PDG2从人肥大细胞中释放的能力或促进膜联蛋白-A1释放的能力来确定。
以下试验说明了本发明:
实施例1:萘啶酸对组胺从人肥大细胞中释放的抑制
方案:使用以下方法培养人源脐带肥大细胞。在补充有100ng/ml的人SCF、50ng/ml的IL-6和1ng/ml的IL-3、以及100μg/ml的青霉素/链霉素(Peprotech,伦敦,英国)的StemSpan(StemCellTechnologies,格勒诺布尔,法国)无血清培养基中,培养商业购得的CD34+干细胞2周。八周之后,在含有10%FCS的StemSpan中培养细胞。每周将细胞传代至新的培养基中。在11至18周之间,经肥大细胞形态学的显微镜检查、c-kit和FcRε1染色(通过FACS)确认后,将细胞用于试验。为评估药效,萘啶酸与等份的在10%FCS培养基中培养的2x105CDMCs(脐带源肥大细胞)孵育5分钟。
组胺释放的测量
使用商业购得的酶免疫测定(SPIbio,斯特拉斯堡,法国)来检测并定量上清液中释放的组胺。按照制造商的方案来进行试验。使用提供的试剂来得到0.39-50nM组胺的标准曲线,且然后在酶标仪中(在405nm处)于60分钟内读取光密度。在一些情况下,通过在攻击之前冻融细胞来确定组胺的总细胞含量。
这些试验的结果在图1中示出。数据清楚地说明了萘啶酸对炎症介质组胺的抑制是剂量相关的。
实施例2:萘啶酸对前列腺素D2从人肥大细胞中释放的抑制
使用实施例1中描述的方法培养人脐带源肥大细胞。
PGD2释放的测量
使用商业购得的酶免疫测定(CaymanChemical,密歇根,美国)来检测并定量上清液中释放的PGD2。按照制造商的方案进行试验。使用提供的试剂来得到78-10,000pg/mlPGD2的标准曲线,然后在酶标仪(在405nm处)中于60分钟内取光密度。
这些试验的结果在图2中示出。数据说明了萘啶酸对炎症性前列腺素PGD2的抑制是剂量相关的。
实施例3:萘啶酸对膜联蛋白-A1从人肥大细胞中释放的促进
使用实施例1中描述的方法培养人脐带源肥大细胞。
通过ELISA测定条件培养基中的Anx-A1蛋白水平。简言之,用1μg抗Anx-A1mAb1B的碳酸氢盐缓冲液(pH9.6)涂布96孔平底ELISA板(Greiner,格洛斯特郡,英国),并在4℃下孵育过夜。在碳酸氢盐缓冲液中洗涤后,在室温下用100μL含1%BSA的PBS阻塞可能未经涂布的位点于1小时。在37℃下,于1小时内加入等份的样品(100μL)或Anx-A1标准溶液(在0.1%吐温-20的PBS中制备;浓度为10μg/mL至0.001μg/mL之间)。在PBS/吐温-20中充分清洗后,加入(在37℃下1小时)100μL多克隆兔抗人Anx-A1血清(Zymed,Invitrogen,佩斯利,英国;在PBS/吐温-20中以1:1000稀释),之后与结合了碱性磷酸酶(1:1000;Sigma)的驴抗兔1gG一起孵育。通过加入100μL对硝基苯磷酸盐(1mg/mL的碳酸氢盐缓冲液,pH9.6)来显色。在酶标仪(TitertekTM,维也纳,奥地利)中405nm处(用620-nm的基准滤光片)读取吸光度。对照标准曲线读出研究样品中的Anx-A1水平,并表示为ng/ml。
图3中示出的结果突出了应答于增大的萘啶酸浓度,而从人肥大细胞中释放的抗炎性膜联蛋白-A1增多。
实施例4:在鼠哮喘模型中对肺部局部给予萘啶酸。
在小鼠哮喘模型中对局部施用萘啶酸的效果进行了研究。在研究的第1天和第14天,通过腹膜内注射使雌性BALB/c小鼠(每组8只动物)对卵清蛋白(OVA,10mg)敏感。在第20、21、22和23天,动物或接受通过鼻内施用对肺部给予的攻击剂量的卵清蛋白(50μg),或接受50μl磷酸盐缓冲生理盐水(PBS,非攻击组)。被OVA攻击的动物还接受了PBS媒介物或通过鼻内施用吸入肺部而给予的萘啶酸(0.3mg/kg体重)。在第21天至第23天,在每次卵清蛋白攻击之前的30分钟和攻击之后的6小时进行上述施用,并且另外在第24天(最后一次攻击和试验终止日之间)进行上述施用。在最终OVA攻击后的48小时,用盐酸氯胺酮(Narketan,2mg/小鼠)和盐酸赛拉嗪(Rompun,0.07mg/小鼠)的组合来麻醉小鼠,并通过颈动脉放血处死小鼠。
按照以下步骤得到支气管肺泡灌洗液(BAL)。插入气管。将磷酸盐缓冲生理盐水(PBS)用作灌洗液,将3份灌洗液(0.4ml;0.3ml;0.3ml;共1mL)缓慢滴入,并使用1ml的BD注射器在连续的3个时刻将其吸出,然后置于Eppendorf管(~1ml)中。
之后将这批Eppendorf管在台式Eppendorf离心机中离心(5min/3500rpm/4℃)。移除上清液,并在涡旋器上通过剧烈震摇封闭在管内的物质使细胞块(cellplugs)再悬浮于600μl的PBS中。然后,移除每份悬浮液的300μl,并置于标记的样品腔内。将过滤卡(Shandon过滤卡,棕色,与0.4ml或更少的样品一起使用,ref#5991023)预装在样品腔和被标记的显微镜载玻片(ThermoScientific,ShandonCytoslide,镀膜的显微镜载玻片,ref#5991056)之间,用夹子固定在一起,并以垂直的状态置于离心机内指定的位置。
在血液分析仪(SysmexXT-2000iV)上,对得到的BALF中的细胞计数。使用MannWhitney检验进行BALF细胞数的统计比较。
该模型的关键方面在于,由对卵清蛋白致敏的免疫反应诱发的嗜酸性粒细胞在BALF中的聚集进行评估。正如所预期的,被致敏的动物在用OVA攻击并由鼻内给予PBS(OVA/OVA/媒介物)时,与未被攻击的动物(OVA/PBS)相比BALF中的嗜酸性粒细胞数显示出显著增多。然而,鼻内施用萘啶酸(OVA/OVA/萘啶酸)使得与被攻击的用媒介物治疗的动物(OVA/OVA/媒介物)相比总BALF嗜酸性粒细胞数显著地且统计学意义(p<0.05)上减少47%(图4)。此外,相对于媒介物治疗的组,在萘啶酸治疗的组中,总细胞数中嗜酸性粒细胞的百分比也显著地且统计学意义上(p<0.05)减少44%(图5)。
这些数据说明了在哮喘模型中萘啶酸在对肺局部给予时的功效,并表明萘啶酸在通过口吸入给予时作为此类病况治疗的潜力。
Claims (18)
1.式(I)的萘啶酸或其类似物或其药物可接受的盐,其用途是治疗或预防炎症性病症
2.根据权利要求1所述的用于所述用途的化合物,其中所述炎症性疾病为:呼吸系统疾病,例如哮喘或慢性阻塞性肺病;慢性退行性疾病,例如风湿性关节炎、骨关节炎或骨质疏松症;皮肤病,例如银屑病、硬皮病或特应性皮炎;慢性脱髓鞘疾病,例如多发性硬化;炎症性肠病,例如溃疡性结肠炎或克罗恩氏病;牙科疾病,例如牙周病或牙龈炎;系统性红斑狼疮;糖尿病性肾病;狼疮性肾炎;IgA肾病或肾小球肾炎;移植物抗宿主病或眼科病。
3.根据权利要求1或2所述的用于所述用途的化合物,其中所述化合物配制用于局部递送。
4.根据权利要求3所述的用于所述用途的化合物,其中所述化合物配制用于对皮肤、肺或胃肠道局部递送。
5.根据前述权利要求中任一项所述的用于所述用途的化合物,其中所述化合物配制用于对皮肤局部递送,且所述病况为例如银屑病、硬皮病或特应性皮炎的皮肤病。
6.根据权利要求1至4中任一项所述的用于所述用途的化合物,其中所述化合物配制用于对肺局部递送,且所述病况为例如哮喘或慢性阻塞性肺病的肺部病况。
7.根据权利要求1至4中任一项所述的用于所述用途的化合物,其中所述化合物配制用于对胃肠道局部递送,且所述病况为例如溃疡性结肠炎或克罗恩氏病的炎症性肠病。
8.根据权利要求1至4中任一项所述的用于所述用途的化合物,其中所述病况为例如牙周病或牙龈炎的牙科疾病。
9.根据权利要求1或2所述的用于所述用途的化合物,其中将所述化合物配制用于全身递送。
10.根据前述权利要求中任一项所述的用于所述用途的化合物,其中所述治疗包括对还施用一种或多种糖皮质激素的患者施用所述化合物,所述糖皮质激素例如为倍氯米松、倍他米松、布地奈德、可的松、地塞米松、氢化可的松、氟替卡松、甲泼尼松、莫美他松、帕拉米松和泼尼松龙。
11.根据前述权利要求中任一项所述的用于所述用途的化合物,其中所述治疗包括向还施用另外的治疗剂的患者施用所述化合物,所述治疗剂选自:抑制血管生成的肽,例如血管生成抑制素;抑制血管生成的类固醇,例如乙酸阿奈可他;VEGF或FGF的调节剂,例如Zactima;配制为眼用的非类固醇抗炎药(NSAID),例如氟比洛芬、双氯芬酸和酮咯酸;糖皮质激素,例如甲基泼尼松龙;白三烯调节剂,例如齐留通;抗组胺药,例如西替利嗪、氯雷他定、酮替芬等;和常规的细胞因子/生长因子调节剂,例如环孢素A、磷酸二酯酶抑制剂等。
12.根据权利要求10或11所述的用于所述用途的化合物,其中所述活性试剂与所述另外的试剂组合提供。
13.包含式(I)的萘啶酸或其类似物或其药物可接受的盐的药物组合物,其用途是治疗或预防炎症性疾病
14.根据权利要求13所述的用于所述用途的药物组合物,其适于局部递送。
15.根据前述权利要求中任一项所述的用于所述用途的化合物或用于所述用途的药物组合物,其中所述化合物为萘啶酸或其药物可接受的盐。
16.根据权利要求1至15中任一项所述的用于所述用途的化合物或用于所述用途的药物组合物,其中所述萘啶酸类似物为式(II)的化合物
其中,
X和X1独立地表示CH或N;
X2表示C(R2)或N;
X4表示C(R4)或N;
R1为H、CF3、CONH2、CN、卤素、NH2、NH-烃基、烃基、环烃基或苯基,并任选地被一个或多个R6取代;其中R1可与R2形成环的部分;
R2为H、CF3、CONH2、CN、卤素、NH2、烃基、O-烃基或S-烃基;其中R2可与R1形成环的部分;
R3为H、CF3、CONH2、CN、卤素、NH2、烃基、O-烃基、吡啶基、环烃基或杂环烃基,并任选地被一个或多个R6取代;其中R3可与R4形成环的部分;
R4为H、F或O-烃基;其中R4可与R3形成环的部分;
R5为H、F、Cl、烃基、O-烃基或NH2;
R6为F、烃基、NH2、NH-烃基、CH2NH2或OH;
或其药物可接受的盐。
17.通过施用式(I)的萘啶酸或式(II)的萘啶酸类似物治疗或预防炎症性病况的方法
其中,
X和X1独立地表示CH或N;
X2表示C(R2)或N;
X4表示C(R4)或N;
R1为H、CF3、CONH2、CN、卤素、NH2、NH-烃基、烃基、环烃基或苯基,并任选地被一个或多个R6取代;其中R1可与R2形成环的部分;
R2为H、CF3、CONH2、CN、卤素、NH2、烃基、O-烃基或S-烃基;其中R2可与R1形成环的部分;
R3为H、CF3、CONH2、CN、卤素、NH2、烃基、O-烃基、吡啶基、环烃基或杂环烃基,并任选地被一个或多个R6取代;其中R3可与R4形成环的部分;
R4为H、F或O-烃基;其中R4可与R3形成环的部分;
R5为H、F、Cl、烃基、O-烃基或NH2;
R6为F、烃基、NH2、NH-烃基、CH2NH2或OH;
或其药物可接受的盐。
18.根据前述权利要求中任一项所述的用于所述用途的化合物、用于所述用途的组合物或方法,其中(I)或(II)或其药物可接受的盐的量不具有实质的抗菌活性。
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB201306411A GB201306411D0 (en) | 2013-04-09 | 2013-04-09 | Treatment of inflammatory conditions |
GB1306413.4 | 2013-04-09 | ||
GB1306411.8 | 2013-04-09 | ||
GB201306413A GB201306413D0 (en) | 2013-04-09 | 2013-04-09 | The local treatment of ophthalmic diseases |
PCT/GB2014/051109 WO2014167327A1 (en) | 2013-04-09 | 2014-04-09 | The treatment of inflammatory disorders |
Publications (1)
Publication Number | Publication Date |
---|---|
CN105431172A true CN105431172A (zh) | 2016-03-23 |
Family
ID=50489339
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201480030407.7A Pending CN105431172A (zh) | 2013-04-09 | 2014-04-09 | 炎症性病症的治疗 |
CN201480030418.5A Pending CN105555364A (zh) | 2013-04-09 | 2014-04-09 | 炎症性眼科疾病的局部治疗 |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201480030418.5A Pending CN105555364A (zh) | 2013-04-09 | 2014-04-09 | 炎症性眼科疾病的局部治疗 |
Country Status (11)
Country | Link |
---|---|
US (2) | US20160051526A1 (zh) |
EP (2) | EP2983788A1 (zh) |
JP (2) | JP2016516762A (zh) |
CN (2) | CN105431172A (zh) |
AU (2) | AU2014252808A1 (zh) |
CA (2) | CA2909117A1 (zh) |
GB (2) | GB2516138C (zh) |
HK (2) | HK1221166A1 (zh) |
RU (2) | RU2015145134A (zh) |
WO (2) | WO2014167326A1 (zh) |
ZA (2) | ZA201507718B (zh) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104496986A (zh) * | 2014-12-12 | 2015-04-08 | 苏州亚科化学试剂股份有限公司 | 萘啶酸的制备方法 |
JP6474913B2 (ja) * | 2015-10-29 | 2019-02-27 | テイカ製薬株式会社 | 外用剤 |
US11510931B2 (en) | 2016-09-28 | 2022-11-29 | Medicon Pharmaceuticals, Inc. | Compositions and methods for treating ophthalmic conditions |
WO2020021035A1 (en) * | 2018-07-26 | 2020-01-30 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Use of antibiotics for the treatment of immunoglobulin a nephropathy |
US20230058189A1 (en) * | 2019-02-08 | 2023-02-23 | Frequency Therapeutics, Inc. | Quinolin-4-one and 4(1h)-cinnolinone compounds and methods of using same |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1228023A (zh) * | 1996-08-20 | 1999-09-08 | 拜尔公司 | 喹诺酮羧酸或萘啶酮羧酸的口服制剂 |
CN1239094A (zh) * | 1998-06-12 | 1999-12-22 | 拜尔公司 | 制备喹诺酮羧酸及其酯和萘啶酮羧酸及其酯的方法 |
CN1259049A (zh) * | 1997-06-04 | 2000-07-05 | 伊莱利利公司 | 可用作5-ht1f激动剂的羧酰胺类 |
WO2003061767A1 (en) * | 2002-01-25 | 2003-07-31 | Atopic Pty Ltd | Methods and compositions for the treatment of asthma and related disorders |
CN1259049C (zh) * | 2001-07-06 | 2006-06-14 | 苏坎波公司 | 包含白介素-2抑制剂和抗菌剂的局部给药组合物 |
WO2009044141A1 (en) * | 2007-10-05 | 2009-04-09 | E-Therapeutics Plc | Compositions comprising cetirizine and a non beta-2-adrenoreceptor agonist, a beta-2-adrenoreceptor agonist or an anti -inflammatory and the use thereof for the treatment of respiratory disorders |
Family Cites Families (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE19729879C2 (de) * | 1997-07-11 | 1999-07-08 | Mann Gerhard Chem Pharm Fab | Lagerstabile ophthalmische Zusammensetzungen, umfassend Diclofenac und Ofloxacin |
CN1090959C (zh) * | 1999-06-17 | 2002-09-18 | 卢世全 | 一种治疗咳喘病的中、西复方成药及制备方法 |
US6552020B1 (en) * | 1999-07-30 | 2003-04-22 | Allergan, Inc. | Compositions including antibiotics and methods for using same |
JP2001342188A (ja) * | 2000-03-27 | 2001-12-11 | Takeda Chem Ind Ltd | 縮合ピラゾール誘導体、その製造法および用途 |
JP3648132B2 (ja) * | 2000-06-19 | 2005-05-18 | 大正薬品工業株式会社 | キノロン系抗菌薬液体製剤及びその包装体 |
ES2967961T3 (es) * | 2004-05-03 | 2024-05-06 | Ipsen Biopharm Ltd | Liposomas útiles en la administración de fármacos |
CN101006076B (zh) * | 2004-06-24 | 2010-09-29 | 沃泰克斯药物股份有限公司 | Atp-结合弹夹转运蛋白的调控剂 |
JP2006028031A (ja) * | 2004-07-12 | 2006-02-02 | Ltt Bio-Pharma Co Ltd | 経粘膜吸収用薬物封入ナノ粒子 |
WO2006039336A2 (en) * | 2004-10-01 | 2006-04-13 | Ramscor, Inc. | Conveniently implantable sustained release drug compositions |
JP2009518312A (ja) * | 2005-12-02 | 2009-05-07 | ヘルス エンハンスメント プロダクツ インク | 疾患を治療するための植物浸出物の組成物および使用 |
US20080138350A1 (en) * | 2006-10-20 | 2008-06-12 | Bennett Michael D | Process for use of fluoroquinolones to reduce or modulate inflammation due to eye disease or ophthalmic surgery |
CN101129386A (zh) * | 2007-07-17 | 2008-02-27 | 长治市三宝生化药业有限公司 | 一种含环丙沙星和地塞米松的局部悬浮滴眼剂 |
CN101801414B (zh) * | 2007-09-21 | 2013-04-03 | 株式会社日本高度医疗研究会 | 口腔用和皮肤用组合物 |
WO2009049238A1 (en) * | 2007-10-11 | 2009-04-16 | The Regents Of The University Of California | Compositions and methods of inhibiting n-acylethanolamine-hydrolyzing acid amidase |
MX2008014515A (es) * | 2008-09-09 | 2010-04-29 | Allergan Inc | Suspension oftalmica para uso ocular. |
DK2346509T3 (da) * | 2008-10-07 | 2020-08-03 | Horizon Orphan Llc | Inhalation af levofloxacin til at reducere lungeinflammation |
MX2012002091A (es) * | 2009-08-19 | 2012-07-03 | Mpex Pharmaceuticals Inc | Uso de antibioticos en aerosol para el tratamiento de la enfermedad pulmonar obstructiva cronica. |
WO2011076721A1 (en) * | 2009-12-22 | 2011-06-30 | Deutsches Krebsforschungszentrum | Fluoroquinolones for the treatment and/or prophylaxis of inflammatory diseases |
MA35070B1 (fr) * | 2011-04-05 | 2014-04-03 | Optosolve Llp | Traitements ophtalmiques |
-
2014
- 2014-04-09 WO PCT/GB2014/051108 patent/WO2014167326A1/en active Application Filing
- 2014-04-09 AU AU2014252808A patent/AU2014252808A1/en not_active Abandoned
- 2014-04-09 CA CA2909117A patent/CA2909117A1/en not_active Abandoned
- 2014-04-09 RU RU2015145134A patent/RU2015145134A/ru not_active Application Discontinuation
- 2014-04-09 WO PCT/GB2014/051109 patent/WO2014167327A1/en active Application Filing
- 2014-04-09 AU AU2014252807A patent/AU2014252807A1/en not_active Abandoned
- 2014-04-09 JP JP2016507059A patent/JP2016516762A/ja active Pending
- 2014-04-09 GB GB1406396.0A patent/GB2516138C/en active Active
- 2014-04-09 GB GB1406390.3A patent/GB2516137B/en active Active
- 2014-04-09 RU RU2015145135A patent/RU2015145135A/ru not_active Application Discontinuation
- 2014-04-09 US US14/783,038 patent/US20160051526A1/en not_active Abandoned
- 2014-04-09 CA CA2909111A patent/CA2909111A1/en not_active Abandoned
- 2014-04-09 CN CN201480030407.7A patent/CN105431172A/zh active Pending
- 2014-04-09 JP JP2016507058A patent/JP2016516761A/ja active Pending
- 2014-04-09 US US14/782,975 patent/US20160068527A1/en not_active Abandoned
- 2014-04-09 CN CN201480030418.5A patent/CN105555364A/zh active Pending
- 2014-04-09 EP EP14717820.6A patent/EP2983788A1/en not_active Withdrawn
- 2014-04-09 EP EP14717821.4A patent/EP2983713A1/en not_active Withdrawn
-
2015
- 2015-10-15 ZA ZA201507718A patent/ZA201507718B/en unknown
- 2015-10-15 ZA ZA2015/07724A patent/ZA201507724B/en unknown
-
2016
- 2016-08-05 HK HK16109377.6A patent/HK1221166A1/zh unknown
- 2016-08-05 HK HK16109376.7A patent/HK1221190A1/zh unknown
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1228023A (zh) * | 1996-08-20 | 1999-09-08 | 拜尔公司 | 喹诺酮羧酸或萘啶酮羧酸的口服制剂 |
CN1259049A (zh) * | 1997-06-04 | 2000-07-05 | 伊莱利利公司 | 可用作5-ht1f激动剂的羧酰胺类 |
CN1239094A (zh) * | 1998-06-12 | 1999-12-22 | 拜尔公司 | 制备喹诺酮羧酸及其酯和萘啶酮羧酸及其酯的方法 |
CN1259049C (zh) * | 2001-07-06 | 2006-06-14 | 苏坎波公司 | 包含白介素-2抑制剂和抗菌剂的局部给药组合物 |
WO2003061767A1 (en) * | 2002-01-25 | 2003-07-31 | Atopic Pty Ltd | Methods and compositions for the treatment of asthma and related disorders |
WO2009044141A1 (en) * | 2007-10-05 | 2009-04-09 | E-Therapeutics Plc | Compositions comprising cetirizine and a non beta-2-adrenoreceptor agonist, a beta-2-adrenoreceptor agonist or an anti -inflammatory and the use thereof for the treatment of respiratory disorders |
Non-Patent Citations (1)
Title |
---|
HIRSHELMANN ROLF ETAL: ""Antiinflammatory action of chemotherapeutic agents and antibiotics"", 《ZEITSHRIFT FURE DIE GESAMTE INNERE MEDIZIN UND IHRE GRENZGEBIETE》 * |
Also Published As
Publication number | Publication date |
---|---|
RU2015145135A (ru) | 2017-05-12 |
ZA201507724B (en) | 2019-02-27 |
HK1221190A1 (zh) | 2017-05-26 |
EP2983713A1 (en) | 2016-02-17 |
AU2014252808A1 (en) | 2015-11-12 |
WO2014167326A1 (en) | 2014-10-16 |
GB2516138C (en) | 2015-12-09 |
CA2909117A1 (en) | 2014-10-16 |
US20160068527A1 (en) | 2016-03-10 |
ZA201507718B (en) | 2019-11-27 |
AU2014252807A1 (en) | 2015-11-12 |
RU2015145134A3 (zh) | 2018-03-16 |
EP2983788A1 (en) | 2016-02-17 |
GB2516138B (en) | 2015-11-25 |
GB2516137B (en) | 2016-02-17 |
GB2516138A (en) | 2015-01-14 |
GB201406396D0 (en) | 2014-05-21 |
WO2014167327A1 (en) | 2014-10-16 |
HK1221166A1 (zh) | 2017-05-26 |
JP2016516761A (ja) | 2016-06-09 |
RU2015145134A (ru) | 2017-05-16 |
GB2516137A (en) | 2015-01-14 |
JP2016516762A (ja) | 2016-06-09 |
US20160051526A1 (en) | 2016-02-25 |
GB201406390D0 (en) | 2014-05-21 |
CN105555364A (zh) | 2016-05-04 |
CA2909111A1 (en) | 2014-10-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU2018205077B2 (en) | Methods of treating autoimmune, respiratory and inflammatory disorders by inhalation of roflumilast N-oxide | |
CN105431172A (zh) | 炎症性病症的治疗 | |
ES2260043T3 (es) | Combinacion sinergica de roflumilast y salmeterol. | |
ES2322725T3 (es) | Composiciones farmaceuticas que contienen un analogo de la nicotina y un inhibidor de la acetilcolinesterasa para la prevencion y el tratamiento de trastornos en el sistema nervioso central. | |
JP6395838B2 (ja) | 神経疾患の処置のためのトラセミド及びバクロフェンを含む組成物 | |
ES2425739T3 (es) | Sorafenib-tosilato para el tratamiento de enfermedades caracterizadas por angiogénesis anormal | |
ES2367722T3 (es) | Nuevos métodos. | |
TW200804341A (en) | Amido compounds and their use as pharmaceuticals | |
US11117865B2 (en) | Inhibitors of bromodomain-containing protein 4 (BRD4) | |
MX2007001567A (es) | Medicamentos para tratar enfermedad respiratoria cronica. | |
MXPA04004393A (es) | Nuevos usos para agentes terapeuticos anti-malarios. | |
IL268125B2 (en) | Pridopidine for the treatment of fragile x syndrome | |
WO2017045612A1 (zh) | 嘧啶衍生物pim激酶抑制剂及其制备方法与在制药中的应用 | |
JP2017128541A (ja) | アポトーシス誘導剤 | |
EP3641763A2 (en) | Cystic fibrosis transmembrane conductance regulator modulators for treating autosomal dominant polycystic kidney disease | |
KR20180033201A (ko) | 진해 조성물 및 방법 | |
ES2378374T3 (es) | Inhibidores de la PDE 4 para el tratamiento de la cistitis intersticial | |
KR20020023675A (ko) | 프레가발린을 포함하는 천식 치료용 제약 조성물 | |
WO2010071582A1 (en) | Pharmaceutical product comprising a muscarinic receptor antagonist and a second active ingredient | |
WO2005063250A1 (ja) | 好中球増多抑制剤 | |
CA3112796A1 (en) | Pharmaceutical composition comprising histone deacetylase inhibitor and methotrexate | |
AR111492A1 (es) | Formulaciones, métodos, kits, y formas de dosificación para tratar dermatitis atópica y para la estabilidad mejorada de un ingrediente farmacéutico activo | |
JP2000302761A (ja) | モルファン誘導体またはその塩 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination |